
<link rel="stylesheet" href="https://bootswatch.com/4/flatly/bootstrap.min.css"><link rel="stylesheet" href="style.css"><script src="https://ajax.googleapis.com/ajax/libs/jquery/3.5.1/jquery.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.16.0/umd/popper.min.js"></script>
<script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.5.2/js/bootstrap.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1">
<div class="header"><div class="top_text"><p id="home">03/21/23</p><p class="summary"><strong> <em>Summary: New data in 3 studies; Expedited timeline in 7 studies; 8 new studies; 1 new FDA IND acceptance; 1 new FDA designation.</em> </strong></p></div><div id="images" class="logos"><img src="data:image/png;base64,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" alt="Lexidyne Logo" width="150" class="lex"><p class="logos">           </p><p class="logos">           </p><p class="logos">           </p><p class="logos">           </p><img src="data:image/png;base64,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" alt="Janssen Logo" width="150" class="jj"> </div></div><h1>Clinical Trials Weekly Digest</h1><br>

<h4><a href="#clinical">Clinical Results Press Releases</a></h4>
<h4><a href="#new_lc">Lung Cancer</a></h4>
<h4><a href="#new_it">Intratumoral</a></h4>
<h4><a href="#new_ct">Cytotoxic</a></h4>
<h4><a href="#new_ia">Immune Activation</a></h4>
<h4><a href="#approvals">Drug Approvals / Applications</a></h4>

<form action="https://getform.io/f/387eb37d-4992-430e-99b3-0bd1f47d1fb2"method="POST" id="interest_form" enctype="multipart/form-data" name="interest_form"><div class="form-group"><br>
<!-- ############################### -->
<!-- ############################### -->
<!-- ###### CLINICAL RESULTS ####### -->
<!-- ############################### -->
<!-- ############################### -->

<h2 id="clinical">Clinical Results Press Releases</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0" class="fda">
  <thead>
    <tr>
      <th><h3>Company</h3></th>
      <th><h3>Update</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>RayzeBio</td>
    <td>RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05477576" target="_blank">ACTION-1 (NCT05477576)</a></td><td><select class="form-select" id="select_form_1" name="NCT05477576"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Phanes Therapeutics</td>
    <td>Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT886 for Advanced Gastric Gastroesophageal Junction and Pancreatic Adenocarcinomas</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05482893" target="_blank">NCT05482893</a></td><td><select class="form-select" id="select_form_2" name="NCT05482893"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Enlivex</td>
    <td>Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05431907" target="_blank">NCT05431907</a></td><td><select class="form-select" id="select_form_3" name="NCT05431907"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Daiichi Sankyo’</td>
    <td>Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity in Distinct Patient Populations with Metastatic Lung and Breast Cancer in Updated Results of Two Early Trials</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04676477" target="_blank">NCT04676477</a></td><td><select class="form-select" id="select_form_4" name="NCT04676477"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Allarity Therapeutics</td>
    <td>Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05571969" target="_blank">NCT05571969</a></td><td><select class="form-select" id="select_form_5" name="NCT05571969"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>CANbridge Pharmaceuticals</td>
    <td>Long-Term Data from CANbridge Pharmaceuticals CAN008 Phase 1/2 Trial in Glioblastoma Multiforme Shows 67% Five-Year Overall Survival Rate Compared to 8.2% in Institutional Database</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02853565" target="_blank">NCT02853565</a></td><td><select class="form-select" id="select_form_6" name="NCT02853565"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Pyxis Oncology</td>
    <td>Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201 a Novel ADC for Solid Tumors</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05720117" target="_blank">NCT05720117</a></td><td><select class="form-select" id="select_form_7" name="NCT05720117"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Anaveon</td>
    <td>Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myeloma</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05641324" target="_blank">OMNIA-2 (NCT05641324)</a></td><td><select class="form-select" id="select_form_8" name="NCT05641324"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>BioNTech</td>
    <td>BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04140526" target="_blank">PRESERVE-001 (NCT04140526)</a></td><td><select class="form-select" id="select_form_9" name="NCT04140526"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo1" class="accordion-toggle" style = "background-color: #E1EBEE;">    <td>Pfizer and Astellas</td>
    <td>Phase 3 Study Shows XTANDI (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02319837" target="_blank">EMBARK (NCT02319837)</a></td><td><select class="form-select" id="select_form_10" name="NCT02319837"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>

<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW LC ############ -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="new_lc">New Trials - Lung Cancer</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Untreated patients with advanced non-small cell lung cancer</td>
    <td>Suzhou Puhe Pharmaceutical Technology Co. LTD</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_1">Study Arms</button></td>
    <td>YK-029A</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05767866" target="_blank">NCT05767866</a></td><td><select class="form-select" id="select_form_11" name="NCT05767866"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations</td>
    <td>Suzhou Puhe Pharmaceutical Technology Co. LTD</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_2">Study Arms</button></td>
    <td><p>YK-209A tablet; Pemetrexed+carboplatin/Cisplatin</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_501">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05767892" target="_blank">NCT05767892</a></td><td><select class="form-select" id="select_form_12" name="NCT05767892"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>BRAF V600 mutation-positive solid tumor</td>
    <td>Cancer Research UK</td>
<td><p>Phase 2|Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_3">Study Arms</button></td>
    <td><p>Vemurafenib; Cobimetinib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_502">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05768178" target="_blank">NCT05768178</a></td><td><select class="form-select" id="select_form_13" name="NCT05768178"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Treatment-resistant EGFR mutant lung cancer</td>
    <td>National Cancer Centre Singapore</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_4">Study Arms</button></td>
    <td>Oral S-1 + Oral Osimertinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05773092" target="_blank">NCT05773092</a></td><td><select class="form-select" id="select_form_14" name="NCT05773092"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo2" class="accordion-toggle">  <td colspan="6"><button type="button" class="btn btn-large btn-outline-primary">VIEW LARGE COMPANY TRIALS</button></td>
  </tr>
 <tr>  <td colspan="12" class="hiddenRow"> <div class="accordian-body collapse" id="demo2"><table class="table table-striped"><thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Advanced or metastatic solid tumors expressing human leukocyte antigen G (HLA-G)</td>
    <td>Hoffmann-La Roche</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_5">Study Arms</button></td>
    <td><p>RO7515629; tocilizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_504">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05769959" target="_blank">NCT05769959</a></td><td><select class="form-select" id="select_form_15" name="NCT05769959"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
</div></td></tr>  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_1" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>In dose-escalation phase previously treated patients with EGFR T790M mutation were enrolled. YK-029A was given at doses of 50 100 150 200 to 250 mg/day (3+3 design).|In dose-escalation phase previously treated patients with EGFR T790M mutation were enrolled. YK-029A was given at doses of 50mg/day and who have no active measurable central nervous system (CNS) metastases.|In dose-escalation phase previously treated patients with EGFR T790M mutation were enrolled. YK-029A was given at doses of 100mg/day and who have no active measurable central nervous system (CNS) metastases.|In dose-escalation phase previously treated patients with EGFR T790M mutation were enrolled. YK-029A was given at doses of 150mg/day and who have no active measurable central nervous system (CNS) metastases.|In dose-extension phase previously treated patients with EGFR exon 20ins mutation were enrolled. YK-029A was given at doses of 150mg/day and who have no active measurable central nervous system (CNS) metastases.|In dose-extension phase previously treated patients with EGFR exon 20ins mutation were enrolled. YK-029A was given at doses of 200mg/day and who have no active measurable central nervous system (CNS) metastases.|In dose-extension phase previously untreated patients with EGFR exon 20ins mutation were enrolled. YK-029A was given at doses of 200mg/day and who have no active measurable central nervous system (CNS) metastases.|In dose-extension phase previously treated patients with EGFR rare mutation (G719X?L861Q?S768I etal.)were enrolled. YK-029A was given at doses of 150mg/day and who have no active measurable central nervous system (CNS) metastases.|In dose-extension phase previously treated patients with EGFR rare mutation (G719X?L861Q?S768I etal.)were enrolled. YK-029A was given at doses of 200mg/day and who have no active measurable central nervous system (CNS) metastases.|In dose-extension phase previously untreated patients with EGFR exon 20ins mutation were enrolled. YK-029A was given at doses of 150mgBID and who have no active measurable central nervous system (CNS) metastases.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: YK-029A</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Part 1: Number of Participants that Experience Adverse Events (AEs) and Serious Adverse Events (SAEs) .|Part 1: Number of Participants with Clinically Significant Abnormal Laboratory Values.|Part 1: Number of Participants with First Cycle Dose-Limiting Toxicities (DLTs).|Part 1: DLTs of Orally Administered YK-029A.|Part 1: Number of Participants with First Cycle Dose-Limiting Toxicities (DLTs).|Part 1: Maximum Tolerated Dose (MTD) of Orally Administered YK-029A|Part 2: Objective Response Rate (ORR) according to RECIST 1.1 by IRC|Part 3: Objective Response Rate (ORR) according to RECIST 1.1 by IRC</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To investigate the safety and tolerability of YK-029A when given orally to patients with advanced NSCLC with EGFR T790M.; Toxicity will be evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.00. DLT will be defined as any of the events specified in the protocol that are considered by the investigator to be at least possibly related to therapy with study medications.; To establish Maximum Tolerated Dose (MTD) (if possible) and Recommended Phase 2 Dose (PR2D) of YK-029A when given orally in patients with advanced NSCLC with EGFR T790M mutations.; The MTD is the highest dose level at which the participant tolerates treatment without dose-limiting toxicities.; Expansion Cohorts 1?2?3 : Confirmed Objective Response Rate (ORR) Assessed by the Independent Review Committee (IRC); xpansion Cohorts 4?5?6?7?8?9 : Confirmed Objective Response Rate (ORR) Assessed by the Independent Review Committee (IRC); Toxicity will be Evaluated According to the NCI CTCAE Version 5.00. DLT will be defined as any of the events specified in the protocol that are considered by the investigator to be at least possibly related to therapy with study medications.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Cycle 1 (Cycle length is equal to [=] 28 days); Up to 36 months after first dose</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_2" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: YK-209A tablet; Drug: Pemetrexed+carboplatin/Cisplatin</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression Free Survival (PFS) as Assessed by Blinded Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 .</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>PFS is defined as the time interval from the date of randomization until the first date at which the criteria for progressive disease (PD) according to RECIST Version 1.1 are met or death whichever occurs first.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to approximately 36 months after the first participant is randomized.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_3" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive a fixed dose of RO7515629 intravenously as a single agent on cycle 0 day -7 and 7 days later on cycle 1 day 1 followed by every three-week dosing frequency. Treatment may continue for up to 12 months maximum or until progression loss of clinical benefit intolerable toxicity withdrawal from study treatment or death.|Participants will receive RO7515629 intravenously as a single agent on cycle 0 day -7 and 7 days later on cycle 1 day 1 followed by every three-week dosing frequency. In case of toxicity step up dosing (single or double) may be implemented. Treatment may continue for up to 12 months maximum or until progression loss of clinical benefit intolerable toxicity withdrawal from study treatment or death.|Participants with selected solid tumors will receive a selected dose of RO7515629 intravenously as a single agent based on the recommended dose sequence for expansion (RDE) and dosing regimen selected from Part I and Part II. Treatment may continue for up to 12 months maximum or until progression loss of clinical benefit intolerable toxicity withdrawal from study treatment or death.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: tocilizumab; Drug: RO7515629</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Part 1 2 3: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Part 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From start of study treatment (cycle 0 day -7 or cycle 0 day -14) until two weeks after second or third RO7515629 infusion (cycle 1 day 1) for a total DLT window of up to 28 days.; Up to 15 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_4" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>This vemurafenib and cobimetinib appendix is for BRAF V600 mutation-positive malignancies occurring in adults.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Vemurafenib; Drug: Cobimetinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response (OR)|Durable Clinical Benefit (DCB)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>An OR is defined as the confirmed occurrence of either a Complete Response (CR) or Partial Response (PR) according to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 criteria (or immune related (ir)-RECIST or standard imaging criteria for specific disease e.g. Response Evaluation in Neuro Oncology criteria (RANO)). In patients with leukaemia OR will be defined as the occurrence of CR  CRi (CR incomplete neutrophil recovery) or CRp (CR with incomplete platelet recovery). The trial will report the proportion of patients with an OR and 95% credible interval.; DCB is defined as the absence of disease progression for at least 24 weeks from the start of trial treatment according to RECIST Version 1.1 criteria (or ir-RECIST or standard imaging criteria for specific disease e.g. RANO criteria). Alternative definitions of DCB based on different time points may be pre-specified for particular sub-cohorts if 24 weeks is not clinically relevant. The trial will report the proportion of patients with a DCB and 95% credible interval.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Disease assessments to be performed up to 24 weeks from the start of trial treatment.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_5" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Oral S-1 + Oral Osimertinib</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Oral S-1 + Oral Osimertinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective response rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The efficacy of S-1 and Osimertinib. ORR is defined as the proportion of subjects who have best objective response (BOR) of CR or PR from start of combination treatment until disease progression or death due to any cause.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######## EXISTING LC ########## -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_lc">Existing Trials - Lung Cancer</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 206 days; Trial completed</strong></td>
    <td>Advanced solid tumors</td>
    <td>Prelude Therapeutics</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_6">Study Arms</button></td>
    <td>PRT1419</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04837677" target="_blank">NCT04837677</a></td><td><select class="form-select" id="select_form_16" name="NCT04837677"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 731 days; Changed status from recruiting to active; Primary Completion Date moved earlier by 238 days</strong></td>
    <td>EGFR mutation-positive NSCLC</td>
    <td>First Affiliated Hospital of Zhejiang University</td>
<td><p>N/A</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_7">Study Arms</button></td>
    <td>Osimertinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04391283" target="_blank">NCT04391283</a></td><td><select class="form-select" id="select_form_17" name="NCT04391283"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 377 days; Primary Completion Date moved earlier by 172 days</strong></td>
    <td>Stage IIIB or IV non-small cell lung cancer</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_8">Study Arms</button></td>
    <td><p>Carboplatin; Paclitaxel; Pevonedistat</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_507">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03965689" target="_blank">NCT03965689</a></td><td><select class="form-select" id="select_form_18" name="NCT03965689"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment decreased by: 300; Changed status from recruiting to withdrawn</strong></td>
    <td>Lung Cancer; Pulmonary Nodules</td>
    <td>Guangdong Provincial People's Hospital</td>
<td><p>N/A</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_9">Study Arms</button></td>
    <td>Vaccine inoculation against SARS-CoV-2</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04894682" target="_blank">NCT04894682</a></td><td><select class="form-select" id="select_form_19" name="NCT04894682"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Enrollment decreased by: 31</strong></td>
    <td>Early stage (I-IIIA) NSCLC</td>
    <td>Intergroupe Francophone de Cancerologie Thoracique</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_10">Study Arms</button></td>
    <td><p>Durvalumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_508">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03030131" target="_blank">NCT03030131</a></td><td><select class="form-select" id="select_form_20" name="NCT03030131"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment decreased by: 29; Changed status from recruiting to withdrawn; Start Date pushed later by 99 days</strong></td>
    <td>Locally advanced or metastatic solid tumors</td>
    <td>Sichuan Baili Pharmaceutical Co. Ltd.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_11">Study Arms</button></td>
    <td>GNC-035</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05039931" target="_blank">NCT05039931</a></td><td><select class="form-select" id="select_form_21" name="NCT05039931"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Enrollment increased by: 182</strong></td>
    <td>Lung Cancer</td>
    <td>Blueprint Medicines Corporation</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_12">Study Arms</button></td>
    <td><p>BLU-451; Carboplatin; Pemetrexed</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_509">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05241873" target="_blank">NCT05241873</a></td><td><select class="form-select" id="select_form_22" name="NCT05241873"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment increased by: 32</strong></td>
    <td>Solid tumors and lymphomas</td>
    <td>Seagen Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_13">Study Arms</button></td>
    <td><p>SEA-TGT; sasanlimab; brentuximab vedotin</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_509">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04254107" target="_blank">NCT04254107</a></td><td><select class="form-select" id="select_form_23" name="NCT04254107"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Enrollment decreased by: 200; Changed status from recruiting to active</strong></td>
    <td>Indeterminate pulmonary nodules</td>
    <td>GuiBin Qiao</td>
<td><p>N/A</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_14">Study Arms</button></td>
    <td>CT scan; Antibiotics; Surgical Resection</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04857333" target="_blank">NCT04857333</a></td><td><select class="form-select" id="select_form_24" name="NCT04857333"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from recruiting to suspended</strong></td>
    <td>Advanced/recurrent solid tumors that express HER2</td>
    <td>Mersana Therapeutics</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_15">Study Arms</button></td>
    <td>XMT-2056</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05514717" target="_blank">NCT05514717</a></td><td><select class="form-select" id="select_form_25" name="NCT05514717"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>EGFR-mutant advanced NSCLC</td>
    <td>ETOP IBCSG Partners Foundation</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_16">Study Arms</button></td>
    <td>Amivantamab; Lazertinib; Zirabev</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05601973" target="_blank">NCT05601973</a></td><td><select class="form-select" id="select_form_26" name="NCT05601973"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>Solid tumors</td>
    <td>Totus Medicines</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_17">Study Arms</button></td>
    <td>TOS-358</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05683418" target="_blank">NCT05683418</a></td><td><select class="form-select" id="select_form_27" name="NCT05683418"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>Unresectable locally-advanced non-small cell lung cancer</td>
    <td>Shanghai Pulmonary Hospital Shanghai China</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_18">Study Arms</button></td>
    <td><p>Serplulimab; Carboplatin; Pemetrexed; Nab-paclitaxel; Surgery; Radiotherapy</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_513">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05766800" target="_blank">NCT05766800</a></td><td><select class="form-select" id="select_form_28" name="NCT05766800"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 731 days</strong></td>
    <td>Anorexia; Lung Non-Small Cell Cancer</td>
    <td>M.D. Anderson Cancer Center</td>
<td><p>Phase 2|Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_19">Study Arms</button></td>
    <td>Anamorelin Hydrochloride; Placebo; Questionnaire Administration</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03637816" target="_blank">NCT03637816</a></td><td><select class="form-select" id="select_form_29" name="NCT03637816"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>Advanced non-small cell lung cancer</td>
    <td>Celgene</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_20">Study Arms</button></td>
    <td><p>nab-paclitaxel IV; CC-486; Duravalumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_514">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02250326" target="_blank">NCT02250326</a></td><td><select class="form-select" id="select_form_30" name="NCT02250326"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 396 days</strong></td>
    <td>Pancreatic cancer non-small cell lung cancer and mismatch repair deficient colorectal cancer that has spread to other places in the body and does not respond to treatment</td>
    <td>M.D. Anderson Cancer Center</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_21">Study Arms</button></td>
    <td><p>Danvatirsen; Durvalumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_514">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02983578" target="_blank">NCT02983578</a></td><td><select class="form-select" id="select_form_31" name="NCT02983578"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 365 days; Start Date pushed later by 365 days</strong></td>
    <td>Solid tumors</td>
    <td>Mabpro a.s.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_22">Study Arms</button></td>
    <td>CA9hu-1</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05698238" target="_blank">NCT05698238</a></td><td><select class="form-select" id="select_form_32" name="NCT05698238"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 731 days; Changed status from recruiting to active; Primary Completion Date moved earlier by 238 days</strong></td>
    <td>EGFR mutation-positive NSCLC</td>
    <td>First Affiliated Hospital of Zhejiang University</td>
<td><p>N/A</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_23">Study Arms</button></td>
    <td>Osimertinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04391283" target="_blank">NCT04391283</a></td><td><select class="form-select" id="select_form_33" name="NCT04391283"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 765 days</strong></td>
    <td>Malignant solid tumors that have a genetic change (mutation) in CKIT or PDGFRA and have spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic)</td>
    <td>M.D. Anderson Cancer Center</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_24">Study Arms</button></td>
    <td><p>Avapritinib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_516">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04771520" target="_blank">NCT04771520</a></td><td><select class="form-select" id="select_form_34" name="NCT04771520"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 546 days; Changed status from completed to active</strong></td>
    <td>Locally advanced or metastatic epithelial malignancies</td>
    <td>Sichuan Baili Pharmaceutical Co. Ltd.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_25">Study Arms</button></td>
    <td>SI-B001</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04603287" target="_blank">NCT04603287</a></td><td><select class="form-select" id="select_form_35" name="NCT04603287"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 91 days; Enrollment increased by: 30</strong></td>
    <td>Solid Tumors</td>
    <td>Vyriad Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_26">Study Arms</button></td>
    <td><p>VSV-IFN-NIS; Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_517">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03647163" target="_blank">NCT03647163</a></td><td><select class="form-select" id="select_form_36" name="NCT03647163"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 366 days</strong></td>
    <td>Early non-small cell lung cancer early stage lung cancer or cancer that has spread to lungs from other parts of the body</td>
    <td>Emory University</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_27">Study Arms</button></td>
    <td><p>Fludeoxyglucose F-18; Positron Emission Tomography (PET); Stereotactic Body Radiation Therapy (SBRT)</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_517">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03493789" target="_blank">NCT03493789</a></td><td><select class="form-select" id="select_form_37" name="NCT03493789"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 377 days; Primary Completion Date moved earlier by 172 days</strong></td>
    <td>Stage IIIB or IV non-small cell lung cancer</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_28">Study Arms</button></td>
    <td><p>Carboplatin; Paclitaxel; Pevonedistat</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_517">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03965689" target="_blank">NCT03965689</a></td><td><select class="form-select" id="select_form_38" name="NCT03965689"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 365 days; Enrollment increased by: 30; Now recruiting; Primary Completion Date pushed later by 1096 days; Start Date pushed later by 92 days</strong></td>
    <td>Resectable NSCLC</td>
    <td>The First Affiliated Hospital of Zhengzhou University</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_29">Study Arms</button></td>
    <td>adjuvant tislelizumab and chemotherapy for MRD+ patients; adjuvant tislelizumab and chemotherapy for MRD+ patients; adjuvant chemotherapy for MRD- patients</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05286957" target="_blank">NCT05286957</a></td><td><select class="form-select" id="select_form_39" name="NCT05286957"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 366 days; Primary Completion Date pushed later by 365 days</strong></td>
    <td>Stage I IIA IIB (and select stage III) NSCLC who have detectable ctDNA after surgery</td>
    <td>Nasser Hanna</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_30">Study Arms</button></td>
    <td><p>Atezolizumab; Docetaxel; Cisplatin; Pemetrexed</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_518">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04367311" target="_blank">NCT04367311</a></td><td><select class="form-select" id="select_form_40" name="NCT04367311"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 91 days; Primary Completion Date pushed later by 122 days</strong></td>
    <td>Locally advanced or metastatic solid tumor</td>
    <td>Sichuan Baili Pharmaceutical Co. Ltd.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_31">Study Arms</button></td>
    <td>BL-B01D1</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05194982" target="_blank">NCT05194982</a></td><td><select class="form-select" id="select_form_41" name="NCT05194982"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 1297 days; Enrollment increased by: 105; Primary Completion Date pushed later by 505 days</strong></td>
    <td>mCRPC</td>
    <td>BioXcel Therapeutics Inc</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_32">Study Arms</button></td>
    <td><p>BXCL701 plus Pembrolizumab; BXCL701 monotherapy</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_519">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03910660" target="_blank">NCT03910660</a></td><td><select class="form-select" id="select_form_42" name="NCT03910660"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Primary Completion Date pushed later by 90 days</strong></td>
    <td>Selected solid tumors</td>
    <td>Celldex Therapeutics</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_33">Study Arms</button></td>
    <td>CDX-527</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04440943" target="_blank">NCT04440943</a></td><td><select class="form-select" id="select_form_43" name="NCT04440943"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Start Date pushed later by 312 days</strong></td>
    <td>Bronchial Epithelial Dysplasia; Chronic Obstructive Pulmonary Disease; Lung Carcinoma</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_34">Study Arms</button></td>
    <td><p>Biospecimen Collection; Bronchial Brush Biopsy; Bronchoscopy; Iloprost; Placebo Administration; Questionnaire Administration</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_520">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05411107" target="_blank">NCT05411107</a></td><td><select class="form-select" id="select_form_44" name="NCT05411107"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo3" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="7"><button type="button" class="btn btn-large btn-outline-primary">VIEW LARGE COMPANY TRIALS</button></td>
  </tr>
 <tr>  <td colspan="12" class="hiddenRow"> <div class="accordian-body collapse" id="demo3"><table class="table table-striped"><thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 412 days; Primary Completion Date moved earlier by 265 days</strong></td>
    <td>Limited stage small cell lung cancer</td>
    <td>Hoffmann-La Roche</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_35">Study Arms</button></td>
    <td><p>Atezolizumab; Tiragolumab; Placebo</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_520">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04308785" target="_blank">NCT04308785</a></td><td><select class="form-select" id="select_form_45" name="NCT04308785"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Primary Completion Date moved earlier by 253 days</strong></td>
    <td>BRAFV600E-mutant metastatic non-small cell lung cancer</td>
    <td>Pfizer</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_36">Study Arms</button></td>
    <td><p>encorafenib; binimetinib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_520">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03915951" target="_blank">NCT03915951</a></td><td><select class="form-select" id="select_form_46" name="NCT03915951"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date moved earlier by 531 days; Primary Completion Date pushed later by 344 days</strong></td>
    <td>Non-Small-Cell Lung Cancer</td>
    <td>Pfizer</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_37">Study Arms</button></td>
    <td><p>Sasanlimab Prefilled syringe; Encorafenib; Binimetinib; Sasanlimab; Axitinib; SEA-TGT</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_520">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04585815" target="_blank">NCT04585815</a></td><td><select class="form-select" id="select_form_47" name="NCT04585815"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment increased by: 140</strong></td>
    <td>Resectable early-stage non-small cell lung cancer</td>
    <td>AstraZeneca</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_38">Study Arms</button></td>
    <td><p>Durvalumab; Oleclumab; Monalizumab; MEDI5752; Dato-DXd; AZD0171; Carboplatin; Cisplatin; Pemetrexed/Cisplatin; Pemetrexed/Carboplatin; Carboplatin/Paclitaxel</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_520">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05061550" target="_blank">NCT05061550</a></td><td><select class="form-select" id="select_form_48" name="NCT05061550"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Expanded Access Status For N C T Id now No longer available</strong></td>
    <td>Unresectable pleural mesothelioma</td>
    <td>Bristol-Myers Squibb</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_39">Study Arms</button></td>
    <td><p>Nivolumab; Ipilimumab; Pemetrexed; Cisplatin; Carboplatin</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_520">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02899299" target="_blank">NCT02899299</a></td><td><select class="form-select" id="select_form_49" name="NCT02899299"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>Stage IB-IIIB (8th AJCC) NSCLC with uncommon EGFRm</td>
    <td>AstraZeneca</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_40">Study Arms</button></td>
    <td>Osimertinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05546866" target="_blank">NCT05546866</a></td><td><select class="form-select" id="select_form_50" name="NCT05546866"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 106 days</strong></td>
    <td>Multiple types of advanced (unresectable and/or metastatic) solid tumors</td>
    <td>Merck Sharp & Dohme LLC</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_41">Study Arms</button></td>
    <td><p>pembrolizumab; pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_521">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02628067" target="_blank">NCT02628067</a></td><td><select class="form-select" id="select_form_51" name="NCT02628067"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date moved earlier by 531 days; Primary Completion Date pushed later by 344 days</strong></td>
    <td>Non-Small-Cell Lung Cancer</td>
    <td>Pfizer</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_42">Study Arms</button></td>
    <td><p>Sasanlimab Prefilled syringe; Encorafenib; Binimetinib; Sasanlimab; Axitinib; SEA-TGT</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_521">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04585815" target="_blank">NCT04585815</a></td><td><select class="form-select" id="select_form_52" name="NCT04585815"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
</div></td></tr>  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_6" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>PRT1419 will be administered by intravenous infusion</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: PRT1419</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose limiting toxicities (DLT) of PRT1419|Maximally tolerated dose (MTD) and/or optimal biological dose (OBD)|Recommended phase 2 dose (RP2D) and schedule of PRT1419</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The RP2D will be established for further investigation in participants with advanced solid tumors.; Dose limiting toxicities will be evaluated through the first cycle; The MTD and/or OBD will be established for further investigation in participants with advanced solid tumors.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline through Day 28; Baseline through approximately 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_7" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Time to discontinuation (TTD)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>"Time to discontinuation (TTD) is defined as the time from the date of first dose of Osimertinib in this study until the date of Osimertinib discontinuation for any reason including disease progression treatment toxicity death or other reason as recorded in CRF. Subjects who are still on treatment at the time of analysis will be censored at the date of last dose received. Lost to follow-up patients will be censored at last documented contact with patient status ""on treatment""."</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>from the date of first dose of Osimertinib in this study until the date of Osimertinib discontinuation for any reason including disease progression treatment toxicity death or other reason as recorded in CRF assessed up to 36 months.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_8" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive paclitaxel IV over 3 hours on day 1 carboplatin IV over 30-60 minutes on day 1 and pevonedistat IV over 1 hour on days 1 3 and 5. Treatment repeats every 21 days for at least 4 cycles in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Carboplatin; Drug: Paclitaxel; Drug: Pevonedistat</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall response rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Defined as the proportion of evaluable subjects with a response. Response will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria. Patients will be re-evaluated for response every 6 weeks. The number and frequencies of responses will be summarized in tabular format. The ORR will be calculated and reported along with the corresponding 95% confidence interval which will be constructed using the Wilson score method.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 5 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_9" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Pulmonary nodules/lung cancer patients who have been vaccinated against the SARS-CoV-2 (with any type/brand of vaccine)|Healthy people who have been vaccinated against the SARS-CoV-2 (with any type/brand of vaccine)|Pulmonary nodules/lung cancer patients who are not vaccinated against the SARS-CoV-2</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Vaccine inoculation against SARS-CoV-2</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Occurence rate of vaccination-related adverse effects|Time to progression of pulmonary nodules|Time to recurrence of lung cancer</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Time calculated from the date of vaccine inoculation to the date of reported progression of pulmonary nodules by CT scan; Occurence rate of vaccination-related adverse effects in case group and healthy control group; Time calculated from the date of vaccine inoculation to the date of reported recurrence of lung cancer confirmed by pathological examination</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Vaccination-related adverse effects are monitored from the time of inoculation up to 1 month after each inoculation; The date of vaccine inoculation to the date of reported progression of pulmonary nodules by CT scan up to 12 months; The date of vaccine inoculation to the date of reported recurrence of lung cancer by pathological examination up to 12 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_10" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>durvalumab 750 mg IV J1 J15 J29</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Durvalumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Surgical resection R0</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Patient percentage of surgical resection R0 after a maximum of 3 cycles of immune therapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>2 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_11" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive GNC-035 as a 24-hour continuous intravenous infusion (cIV QD) for 2 weeks (a 2-week cycle). Participants with no intolerable AEs could continue for another three cycles.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: GNC-035</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>DLT|MTD or MAD|TEAE|The recommended dose for future clinical study</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Treatment-Emergent Adverse Event; The recommended dose for future clinical study; Dose limiting toxicity; Maximum tolerated dose or maximum administrated dose</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 2 years; Up to 2 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_12" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>BLU-451 monotherapy with dose escalation in participants with metastatic cancer with EGFR Ex20ins or other selected EGFR mutations that have progressed after prior systemic therapies.|BLU-451 with dose escalation in combination with carboplatin and pemetrexed in participants with metastatic NSCLC with common EGFR mutations. This arm will enroll participants only in the United States.|BLU-451 enrichment at select doses.|EGFR Ex20ins participants who have previously received platinum-based chemotherapy and either amivantamab or mobocertinib will receive BLU-451.|EGFR Ex20ins participants who have previously received platinum-based chemotherapy but have not received a prior EGFR Ex20ins-targeted agent will receive BLU-451.|EGFR Ex20ins participants with at least one measurable lesion in brain per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 who have previously received platinum-based chemotherapy will receive BLU-451. Previous treatment with EGFR Ex20Ins-targeted therapies is allowed but not required.|Participants with EGFR Ex20ins who have previously received platinum-based chemotherapy and both amivantamab AND mobocertinib OR received any investigational Ex20Ins targeted agent(s) will receive BLU-451. Participants with Ex20ins or atypical mutations enrolled in other cohorts and who have other oncogenic drivers by central testing at baseline will be moved to this arm.|Participants with EGFR Ex20ins who have not received prior systemic therapy in metastatic setting will receive BLU-451.|Participants with EGFR atypical mutations (e.g. G719X L861Q) who have previously received at least one EGFR tyrosine kinase inhibitor (TKI) will receive BLU-451. Participants with with other atypical EGFR mutations such as S768I may be enrolled if approved by Sponsor Medical Monitor.|Participants with EGFR atypical mutations (e.g. G719X L861Q) who have not received prior systemic therapy in metastatic setting will receive BLU-451. Participants with with other atypical EGFR mutations such as S768I may be enrolled if approved by Sponsor Medical Monitor.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Carboplatin; Drug: BLU-451; Drug: Pemetrexed</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase I - Determine the maximum tolerated dose (MTD) of BLU-451|Phase I - Determine the Recommended Phase 2 Dose (RP2D) of BLU-451|Phase I - Rate and severity of Adverse Events (AEs) of BLU-451|Phase II - The Overall Response Rate (ORR) rate of BLU-451</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>ORR is defined as the proportion of subjects with objective response of CR or PR as determined by the Investigator using RECIST v1.1.; MTD determination: Dose-limiting toxicities (DLTs) rate; RP2D determination: DLT PK PD and preliminary safety data</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>12-15 Months; Up to 30 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_13" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>SEA-TGT|SEA-TGT + sasanlimab|SEA-TGT + brentuximab vedotin</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: sasanlimab; Drug: SEA-TGT; Drug: brentuximab vedotin</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of participants with adverse events (AEs)|Number of participants with laboratory abnormalities by grade|Number of participants with a dose-limiting toxicity (DLT) at each dose level</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To be summarized using descriptive statistics; An AE is any untoward medical occurrence in a subject or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 21 days; Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_14" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients are recommended for using antibiotics solely follow-up or surgical resection according to the current clinical guideline for management of indeterminate pulmonary nodule. No intervention is administered for this observatory study.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Antibiotics; Procedure: Surgical Resection; Diagnostic Test: CT scan</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Time to surgical resection|Time to progression</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Time calculated from the date of identification of pulmonary nodule to the date of progression of pulmonary nodule based on evaluation of CT imaging; Time calculated from the date of identification of pulmonary nodule to the date of surgical resection</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>The date of first documented diagnosis of pulmonary nodule by CT scan to the date of documented progression by CT scan up to 60 months; The date of first documented diagnosis of pulmonary nodule by CT scan to the date of surgical resection up to 60 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_15" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>XMT-2056 alone (monotherapy)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: XMT-2056</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Frequency of dose-limiting toxicities (DLTs) associated with XMT-2056 during the first cycle of treatment (Dose Escalation)|Incidence of adverse events (Dose Escalation and Dose Expansion)|Objective Response Rate (ORR) (Dose Expansion)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Determine the maximum tolerated dose (MTD) of XMT-2056; Assess the safety and tolerability of XMT-2056 by determining the number of patients with adverse events from date of first dose to 30 days post last dose.; The percentage of patients with a best overall response of confirmed complete or partial response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>15 months; 3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_16" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Amivantamab (fixed dose of 1750 mg (or 2100 mg i.v. every 3 weeks until disease progression or intolerable toxicity) PLUS Lazertinib (240 mg orally once daily until disease progression or intolerable toxicities) PLUS Bevacizumab (Zirabev® is administered at a dose of 15mg/kg i.v. every 3 weeks until disease progression or intolerable toxicity).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Zirabev; Drug: Lazertinib; Drug: Amivantamab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Efficacy of amivantamab and bevacizumab added to continued treatment with a third-generation EGFR-TKI (osimertinib or lazertinib)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The primary endpoint to assess the efficacy of amivantamab and bevacizumab added to continued treatment with a third-generation EGFR-TKI (osimertinib or lazertinib) is the objective response rate (ORR) investigator assessed at 12 weeks according to RECIST v1.1. ORR is defined as the rate of patients among all enrolled patients that achieve a best overall response [complete response (CR) or partial response (PR)] across all post-enrolment tumour-assessment time-points.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>from date of enrolment until 12 weeks of follow-up.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_17" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Multiple doses of TOS-358 for oral administration.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: TOS-358</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Determine the rate of dose-limiting toxicities (DLTs)|Incidence and severity of adverse events (AEs) and specific laboratory abnormalities graded according to NCI CTCAE v5</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>First 21 days of treatment; Start of treatment to 30 days after last dose</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_18" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental; Other</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>In this arm patients with tumors resectable after chemoimmunotherapy will receive surgical treatment in department of thoracic surgery.|In this arm patients with tumors resectable after chemoimmunotherapy will receive radiotherapy in department of medical oncology.|In this arm patients with tumors still unresectable after chemoimmunotherapy will receive therapy in department of medical oncology.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Radiation: Radiotherapy; Drug: Nab-paclitaxel; Drug: Carboplatin; Drug: Pemetrexed; Drug: Serplulimab; Procedure: Surgery</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Event-free survival (EFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Event-free survival (EFS) is defined as the length of time (months) from randomization to any of the following events: any progression of disease precluding surgery progression or recurrence disease based on response evaluation criteria in solid tumors (RECIST) 1.1 after surgery or death due to any cause. Participants who don't undergo surgery for reason other than progression will be considered to have an event at progression or death. Progression is defined as at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study. In addition to the relative increase of 20% the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 30 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_19" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Placebo Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive anamorelin hydrochloride PO daily for 9 weeks in the absence of disease progression or unaccepted toxicity.|Patients receive placebo PO daily for 9 weeks in the absence of disease progression or unaccepted toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Other: Placebo; Other: Questionnaire Administration; Drug: Anamorelin Hydrochloride</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>To reach thematic saturation by qualitatively examining experiences related to anorexia at the baseline in advanced lung cancer patients with anorexia/cachexia receiving either oral Anamorelin 100 mg or placebo.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>"A 60-90 minute interview will be conducted to identify and explore a range of issues including: impact on daily psycho-social function (relationships work mood initiative pleasurable activities); food intake; independence; physiological changes in appetite/eating; visuality of cachexia; weight loss interpreted as a ""bad sign""; response from health care professionals; conflict over food; coping responses; and the patient's report of meaningful change in symptoms due to the intervention (and if so why)."</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline up to day 64</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_20" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Subjects in the combination arm will receive nab-paclitaxel 100 mg^/m2 intravenous (IV) infusion over 30 minutes on Days 8 and 15 and CC-486 200 mg orally daily (QD) on Days 1 to14 of each 21-day treatment cycle|Subjects in the monotherapy arm will receive nab-Paclitaxel 100 mg/m^2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day treatment cycle|subjects in the nab-Paclitaxel/durvalumab combination arm will receive nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and durvalumab 1125 mg IV infusion over approximately 1 hour on Day 15 of each 21-day treatment cycle</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Duravalumab; Drug: nab-paclitaxel IV; Drug: CC-486</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Kaplan Meier Estimate of Progression-Free Survival (PFS) as Assessed by the Investigator</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Progression-free survival was defined as the time in months from the date of randomization/assignment to the date of disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria documented by computed tomography (CT) scan not including symptomatic deterioration or death (any cause) on or prior to the clinical cut-off date which ever occurred earlier. Participants who did not have disease progression and had not died regardless of whether they were discontinued from treatment were censored at the date of last tumor assessment on or prior to the clinical cut-off date that the participant was progression free. Progressive Disease was defined as at least a 20% increase in the sum of diameters of target lesions from nadir.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From date of first dose of IP to DP; up to data cut-off date of 30 August (Aug) 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 December (Dec) 2017 for Durva + nab-paclitaxel; participants were followed for PFS for up to 18 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_21" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive danvatirsen IV over 1 hour on days 7 5 and 3 prior to cycle 1 then on days 1 8 15 and 22. Patients also receive durvalumab IV over 1 hour on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Durvalumab; Drug: Danvatirsen</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of adverse events (AEs) serious AEs|Physiological parameters (Laboratory evaluations)|Incidence of treatment-emergent AEs (TEAEs) SAEs and death(s)|PD-L1 expression|Phosphorylated or total STAT3 expression levels|Characterization of immune infiltrates|Quantification and characterization of CD8 staining pattern|PD-L1 protein levels in the membrane of circulating tumor cells|Physiological parameters|Physical Examinations</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>A complete physical examination is required at screening before dosing on Day 7 of the Lead in before dosing on Day 1 of each cycle and at the EOT visit. A targeted physical examination as directed by disease signs and symptoms is required before dosing on Day 15 of each cycle.; Will be graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.03.; Vital signs will required at screening before dosing on Day -7 of the Lead-in; before dosing on Days 1 8 15 and 22 of each cycle; and at the EOT visit.; Blood samples for routine coagulation assessments will be obtained at screening and once during week 4 of cycle 1.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 4 years; Baseline up to 4 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_22" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: CA9hu-1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of adverse events to CA9hi-1 and grading their severity according to the National Cancer Institute's Common Terminology Criteria for adverse Events (NCI CTCAE) Version 4.02.|Number of patients reaching the dose levels of 750 mg of CA9hu-1 without any dose limiting toxicities.|Number of patients reaching pharmacologically active dose measurement of CA9hu-1|Maximum tolerated dose of CA91hu-1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The objective is to determine a dose at which no more than one patient out of up to six patients at the same dose level experience a highly probable or probable CA9hu-1 related dose limiting toxicity.; The primary objective of this outcome is to establish the safety and toxicity profile of hu-CA91.; The objective of this outcome is to perform a dose escalation of of CA9hu-1 to levels of 750mg without any dose limiting toxicities.; The objective of this outcome is to determine number of patients in whom the pharmacologically active dose of CA9hu-1 wil be reached by measurement of plasma concentrations of the CA9hu-1. In order to reach the proposed pharmacologically active dose the plasma levels of 200 +/- 100 nM are necessary.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>4 weeks; 6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_23" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Time to discontinuation (TTD)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>"Time to discontinuation (TTD) is defined as the time from the date of first dose of Osimertinib in this study until the date of Osimertinib discontinuation for any reason including disease progression treatment toxicity death or other reason as recorded in CRF. Subjects who are still on treatment at the time of analysis will be censored at the date of last dose received. Lost to follow-up patients will be censored at last documented contact with patient status ""on treatment""."</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>from the date of first dose of Osimertinib in this study until the date of Osimertinib discontinuation for any reason including disease progression treatment toxicity death or other reason as recorded in CRF assessed up to 36 months.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_24" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive avapritinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Avapritinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall response rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>ORR defined as confirmed complete response (CR) or partial response (PR) from the time of study treatment initiation until disease progression as centrally assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or Response Assessment in Neuro-Oncology Criteria (RANO) criteria as appropriate. Confirmed CR or PR will be defined as a repeat assessment performed 4 weeks (+/-3 days) after the criteria for response is first met. Will estimate ORR along with 90% confidence interval according to Clopper-Pearson method for each cohort and for specific tumor type.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>or date of death from any cause whichever came first assessed up to 50 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_25" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants receive SI-B001 as intravenous infusion for the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: SI-B001</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase Ia: Dose limiting toxicity (DLT)|Phase Ia: Maximum tolerated dose (MTD)|Phase Ib: Recommended Phase II Dose (RP2D)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>MTD is defined as the highest dose level at which no more than 1 in 6 participants experienced a DLT during the first cycle (within 28 days of the first administration).; The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study based on safety tolerability efficacy PK and PD data collected during the dose escalation study of SI-B001.; DLTs are assessed according to NCI-CTCAE v5.0 during the first cycle (28 days) and defined as occurrence of any of the toxicities in DLT definition if judged by the investigator to be possibly probably or definitely related to study drug administration.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 28 days after the first dose of SI-B001</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_26" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients with pembrolizumab refractory solid tumors will receive a single IV dose of 5e10 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 1 then every 21 days up to 2 years.|Patients with pembrolizumab refractory Neuroendocrine Carcinoma (NEC) or non small cell lung cancer (NSCLC) will receive a single IV dose of 1.0e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 8 then every 21 days up to 2 years.|Patients with pembrolizumab refractory Neuroendocrine Carcinoma (NEC) will receive a single IV dose of 1.0e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 8 then every 21 days up to 2 years.|Patients with pembrolizumab refractory non small cell lung cancer (NSCLC) will receive a single IV dose of 1.0e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 8 then every 21 days up to 2 years.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Pembrolizumab; Biological: VSV-IFNβ-NIS</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Expansion arms: Overall response rate (ORR)|Safety run-in arm: Number of participants with treatment related adverse events (NCI CTCAE; Version 4.03)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>proportion of patients in the analysis population who have complete response (CR) or partial response (PR) based on RECIST 1.1 imaging; Assessment of safety and toxicity of intravenous VSV-IFNβ-NIS in combination with pembrolizumab therapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>43 days - 6 months; 21 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_27" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants receive fludeoxyglucose F-18 IV and after 60 minutes undergo positron emission tomography (PET) within 4 weeks of the first planned stereotactic body radiation therapy (SBRT) fraction prior to the second planned fraction and prior to the fifth planned fraction.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Procedure: Positron Emission Tomography (PET); Radiation: Stereotactic Body Radiation Therapy (SBRT); Drug: Fludeoxyglucose F-18</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Change in metabolic tumor volumes measuring inter-fraction variability of fludeoxyglucose F-18-PET (FDG) - positron emission tomography (PET) activity of thoracic stereotactic body radiation therapy (SBRT) target volumes|Change in total lesion glycolysis values measuring inter-fraction variability of fludeoxyglucose F-18-PET (FDG) - positron emission tomography (PET) activity of thoracic stereotactic body radiation therapy (SBRT) target volumes</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Total lesion glycolysis values across the treatment continuum i.e. pre-treatment before second fraction and before the last fraction of treatment will be compared. The observed % change from baseline will be calculated at all time points for all 15 patients and for every tumor treated with SBRT.; Metabolic tumor volumes across the treatment continuum i.e. pre-treatment before second fraction and before the last fraction of treatment will be compared. The observed % change from baseline will be calculated at all time points for all 15 patients and for every tumor treated with SBRT.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 6 weeks from study start</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_28" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive paclitaxel IV over 3 hours on day 1 carboplatin IV over 30-60 minutes on day 1 and pevonedistat IV over 1 hour on days 1 3 and 5. Treatment repeats every 21 days for at least 4 cycles in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Carboplatin; Drug: Paclitaxel; Drug: Pevonedistat</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall response rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Defined as the proportion of evaluable subjects with a response. Response will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria. Patients will be re-evaluated for response every 6 weeks. The number and frequencies of responses will be summarized in tabular format. The ORR will be calculated and reported along with the corresponding 95% confidence interval which will be constructed using the Wilson score method.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 5 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_29" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>MRD+: Tislelizumab 200mg Q3W + chemotherapy 1-4 cycles and followed by Tislelizumab 200mg Q3W Up to 16 cycles or until PD or intolerable toxicity or withdrawal||MRD-: Adjuvant chemotherapy and surveillance the MRD status the patient will receive treatment for MRD+ patient when MRD detected|patients in non MRD-guided arm receive adjuvant tislelizumab and chemotherapy</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: adjuvant chemotherapy for MRD- patients; Drug: adjuvant tislelizumab and chemotherapy for MRD+ patients</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>2-year PFS rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Progression-free survival (per RECIST 1.1) is defined as the time from the starting date of study drug to the date of first documentation of disease progression or death whichever occurs first. Subjects who do not have disease progression will be censored at their last valid tumor assessment. PFS rate at 1 year as estimated by Kaplan-Meier method.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>up to 36 months after enrollment or study close</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_30" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Atezolizumab 1200mg Pemetrexed 500 mg/m^2 Cisplatin 60-75 mg/m^2|Atezolizumab 1200mg Docetaxel 60-75 mg/m^2 Cisplatin 60-75 mg/m^2</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Atezolizumab; Drug: Cisplatin; Drug: Pemetrexed; Drug: Docetaxel</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Percentage of patients with undetectable ctDNA after 4 cycles of adjuvant chemotherapy + Atezolizumab plus up to 13 additional cycles of Atezolizumab in patients with stage I (tumors ≥ 4cm) IIA IIB and select stage III [any T1-3 N1-2 and T4N0-2]</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To estimate the percentage of patients with undetectable circulating tumor DNA (ctDNA) after 4 cycles of adjuvant chemotherapy + Atezolizumab plus up to 13 additional cycles of Atezolizumab in patients with stage I (tumors ≥ 4cm) IIA IIB and select stage III [any T1-3 N1-2 and T4N0-2] NSCLC who have detectable ctDNA after surgery but prior to adjuvant therapy.; At each time point ctDNA detection status (detectable or not detectable) will be determined by CAPP-seq using the Monte Carlo-based ctDNA detection index cutoff point of  0.05 as described by Newman et al [53 54]. If ctDNA detection index is  0.05 ctDNA will be classified as not detected at that time point whereas if  0.05 then it will be classified as detected.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 17 cycles (13 months)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_31" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: BL-B01D1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase Ia: Dose limiting toxicity (DLT)|Phase Ia: Maximum tolerated dose (MTD)|Phase Ib: Recommended Phase II Dose (RP2D)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>MTD is defined as the highest dose level at which no more than 1 in 6 participants experienced a DLT during the first cycle .; DLTs are assessed according to NCI-CTCAE v5.0 during the first cycle and defined as occurrence of any of the toxicities in DLT definition if judged by the investigator to be possibly probably or definitely related to study drug administration.; The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study based on safety tolerability efficacy PK and PD data collected during the dose escalation study of BL-B01D1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 21 days after the first dose</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_32" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Other</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients will be observed for dose-limiting toxicity (DLT) during Cycle 1. 3 patients will be treated initially with 0.4 mg BXCL701 plus PEMBRO:||If there are no DLTs the dose of BXCL701 will be escalated to 0.6 mg in the next cohort.||If ≥1/3 of patients has a DLT in Cycle 1 either 3 patients (if 1 experience a DLT) or 6 to 9 patients (if 2 or 3 experiences a DLT) will be added at the 0.4 mg dose.||At the 0.4mg dose:||If 1/3 of the patients experience a DLT consideration will be given to dose to 0.6 mg BXCL701 plus PEMBRO.||If 1/3 of the patients experience a DLT the Phase 2a can commence. If 1/3 of the patients experience a DLT a discussion will be held as to how to proceed.||Following 0.6 mg dose. If there are no DLTs the Phase 2a can commence. If ≥1/3 patients have a DLT in Cycle 1 after a discussion 6 to 9 patients will be added at the 0.6 mg dose.||For this cohort of 6 to 9 patients:||If /=1/3 of the patients experience a DLT the Phase 2a can commence|After assessment of the safety and confirmation of the BXCL701/+PEMBRO dose schedule to be used in the subsequent stage the Phase 2a will begin. Eligible patients will receive BXCL701 QD on Days 1 to 14 of a 21-day cycle plus PEMBRO 200 mg administered IV on Day 1 every 21 days.|Upon completion of the Phase 2a and achievement of the protocol required composite responses for a given histologic subtype the Phase 2b enrollment will begin for that subtype. Eligible patients will be randomized to receive:||• Combination therapy of BXCL701 on Days 1 to 14 of a 21-day cycle plus PEMBRO 200 mg administered IV on Day 1 of every 21 days.|Upon completion of the Phase 2a and achievement of the protocol required composite responses for a given histologic subtype the Phase 2b enrollment will begin for that subtype. Eligible patients will be randomized to receive:||Monotherapy BXCL701 on Days 1 to 14 of a 21-day cycle. Upon radiographic disease progression with monotherapy crossover to combination treatment is allowed.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: BXCL701 plus Pembrolizumab; Drug: BXCL701 monotherapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase 2a: Estimate the composite response rate of the combination of BXCL701 + PEMBRO|Phase 2b: Evaluate response rates in patients treated with the combination of BXCL701 + PEMBRO and with BXCL701 monotherapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria; circulating tumor cell (CTC) conversion from 5/7.5 mL to 5/7.5 mL per Veridex assay; and 50% or greater prostate-specific antigen (PSA) decline from baseline.; To evaluate the response rates defined by RECIST 1.1 criteria by histologic subtype in patients treated with the combination of BXCL701 + PEMBRO and with BXCL701 monotherapy.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>up to 36 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_33" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Dose-escalation phase: Eligible patients will receive CDX-527 treatment based on cohort assigned until progression or intolerance.||Expansion phase: Patients will receive CDX-527 at the dose level(s) chosen during the escalation phase.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: CDX-527</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety and Tolerability of CDX-527 as assessed by CTCAE v5.0</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The rates of drug-related adverse events will be summarized and maximum tolerated dose will be determined.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From first dose through 28 days after last dose</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_34" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Placebo Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive Iloprost PO BID for a 180 days in the absence of unacceptable toxicity. Patients undergo bronchoscopy with biopsies and brushings at day 180.|Patients receive placebo PO BID for a 180 days in the absence of unacceptable toxicity. Patients undergo bronchoscopy with biopsies and brushings at day 180.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Procedure: Bronchial Brush Biopsy; Other: Questionnaire Administration; Procedure: Bronchoscopy; Drug: Placebo Administration; Procedure: Biospecimen Collection; Drug: Iloprost</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Change in numerical grade of the worst (highest grade on the WHO scale) dysplastic lesion per subject on bronchoscopy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Histologic response is the mean change between baseline and 6 month follow up bronchoscopy in the numerical grade of the worst (highest grade on the World Health Organization [WHO] scale) dysplastic lesion per subject. Will be analyzed using a linear regression models with post-treatment worst grade dysplasia as the outcome variable and treatment arm (iloprost and placebo) and baseline worst grade dysplasia as predictors.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline to 6 month follow up</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_35" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive atezolizumab + tiragolumab intravenously on the first day of each cycle. One cycle of therapy will be defined as 21 days. Atezolizumab and tiragolumab treatment will continue up to 17 doses unless investigator-assessed loss of clinical benefit unacceptable toxicity investigator or patient decision to withdraw from therapy or death (whichever occurs first).|Participants will receive atezolizumab + placebo on the first day of each cycle. One cycle of therapy will be defined as 21 days. Atezolizumab and placebo treatment will continue up to 17 doses unless investigator-assessed loss of clinical benefit unacceptable toxicity investigator or patient decision to withdraw from therapy or death (whichever occurs first).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Other: Placebo; Drug: Atezolizumab; Drug: Tiragolumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Investigator Assessed Progression-Free Survival (PFS) in the Intent-To-Treat (ITT) Population</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>PFS is defined as the time from randomization to the first occurrence of disease progression or death from any cause whichever occurs first. PFS will be calculated based on disease status evaluated by the investigator according to RECIST v1.1.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Randomization up to approximately 48 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_36" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Study treatment with encorafenib and binimetinib will be self-administered orally without regard to food.||Patients will receive the following per 28-day (± 3 days) cycle:||Encorafenib: 450 mg (6 × 75 mg capsule) once daily (QD)|Binimetinib: 45 mg (3 × 15 mg tablet) twice daily (BID)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: encorafenib; Drug: binimetinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate (ORR) as Determined by Independent Radiology Review (IRR) per RECIST v1.1 in the Treatment Naïve and Previously Treated Settings</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_37" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Sasanlimab will be administered subcutaneously. Encorafenib & binimetinib will be administered orally. Treatments will be administered until progressive disease unacceptable AE participant withdraws or study is terminated.|Sasanlimab will be administered subcutaneously. Axitinib will be administered orally. SEA-TGT will be administered intravenously. Treatments will be administered until progressive disease unacceptable AE patient withdraws or study is terminated.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Binimetinib; Drug: Sasanlimab Prefilled syringe; Drug: Encorafenib; Drug: Sasanlimab; Drug: SEA-TGT; Drug: Axitinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Percentage of participants with Dose-limiting toxicities (DLT)|Durable Objective Response Rate - Percentage of Participants With Objective Response|Objective Response Rate-Percentage of Participants with Objective Response</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Sub-Study A only Phase 2 only: Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) lasting for at lease 10 months according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1).; Phase 1 Primary Outcome: DLTs are a predefined set of observed adverse events that are at least possibly related to at least 1 of the investigational agents.; Sub-Study B only Phase 2 only: Percentage of participants with CR or PR according to RECIST v1.1.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>First dose (Cycle 1 Day 1) to end of first treatment cycle (about 21-28 days); First dose (Cycle 1 Day 1) to End of Treatment (up to about 24 months); each cycle is about 21 days; First dose (Cycle 1 Day 1) to End of Study Treatment (up to about 24 months); each cycle is about 28 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_38" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive Durvalumab + Oleclumab + platinum doublet chemotherapy as neoadjuvant treatment and Durvalumab + Oleclumab as adjuvant treatment.||Participants will receive one of the following chemotherapy regimens based on the tumour histology and Investigator's discretion as part of their treatment regimen prior to surgery:||Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin|Participants will receive Durvalumab + Monalizumab + platinum doublet chemotherapy as neoadjuvant treatment and Durvalumab + Monalizumab as adjuvant treatment.||Participants will receive one of the following chemotherapy regimens based on the tumour histology and Investigator's discretion as part of their treatment regimen prior to surgery:||Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin|Participants will receive MEDI5752 + platinum doublet chemotherapy as neoadjuvant treatment and MEDI5752 as adjuvant treatment.||Participants will receive one of the following chemotherapy regimens based on the tumour histology and Investigator's discretion as part of their treatment regimen prior to surgery:||Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin|Participants will receive Dato-DXd + durvalumab + single agent platinum as neoadjuvant treatment and durvalumab as adjuvant treatment.||Participants will receive one of the following chemotherapy regimens based on physician choice of as part of their treatment regimen prior to surgery:||Carboplatin or Cisplatin|Participants will receive AZD0171 + durvalumab + platinum doublet chemotherapy as neoadjuvant treatment and AZD0171 + durvalumab as adjuvant treatment.||Participants will receive one of the following chemotherapy regimens based on the tumour histology and Investigator's discretion as part of their treatment regimen prior to surgery:||Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Carboplatin/Paclitaxel; Drug: AZD0171; Drug: Oleclumab; Drug: Carboplatin; Drug: Pemetrexed/Carboplatin; Drug: Dato-DXd; Drug: Pemetrexed/Cisplatin; Drug: Cisplatin; Drug: MEDI5752; Drug: Durvalumab; Drug: Monalizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of participants with pathological complete response (pCR)|Number of participants with adverse events (AEs) and serious adverse events (SAEs)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From randomization to approximately 15 weeks after the first dose of study interventions; Until Day 90 after the last dose of study interventions (Up to approximately 3 years)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_39" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Specified dose on specified days|Specified dose on specified days</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Nivolumab; Drug: Carboplatin; Drug: Cisplatin; Drug: Pemetrexed; Biological: Ipilimumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall Survival (OS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Overall Survival was defined as the time from randomization to the date of death due to any cause. A participant who has not died was censored at last known date alive.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From randomization to the date of death (Up to 40 Months)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_40" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Subjects successfully enrolled into the study will receive 80mg osimertinib QD p.o. until completion of planned treatment duration recurrence of disease or other treatment discontinuation criteria is met. The maximum treatment duration period is 3 years.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Osimertinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>3-year disease-free survival (DFS) rate by investigator assessment</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>DFS is defined as the time from the first dosing of study treatment until the date of disease recurrence by investigator assessment or death by any cause in the absence of disease recurrence. DFS rate at 3 years is defined as the proportion of patients alive and disease free at 3 years from the first dosing of study treatment as estimated by Kaplan-Meier method respectively. Patients who are disease-free and alive at the time of analysis will be censored at the date of their latest follow-up assessment known to be disease-free.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 3 years for each subject from the first dosing of study treatment.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_41" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive pembrolizumab 200 mg intravenously on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years of treatment).|Participants with any advanced solid tumor that has failed at least one line of therapy and is Tumor- Mutational Burden-High (TMB-H) excluding participants with mismatch repair deficient (dMMR/MSI-H) tumors. The dosing regimen for this cohort will be 400 mg every 6 weeks (Q6W) for up to 18 administrations (up to approximately 2 years of treatment).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ at any time during the trial. Responses will be determined by independent central radiologic review with confirmatory assessment as required per RECIST 1.1. Participants with unknown or missing response information will be treated as non-responders. The percentage of participants who experience a CR or PR based on modified RECIST 1.1 will be presented.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to approximately 10.5 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_42" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Sasanlimab will be administered subcutaneously. Encorafenib & binimetinib will be administered orally. Treatments will be administered until progressive disease unacceptable AE participant withdraws or study is terminated.|Sasanlimab will be administered subcutaneously. Axitinib will be administered orally. SEA-TGT will be administered intravenously. Treatments will be administered until progressive disease unacceptable AE patient withdraws or study is terminated.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Binimetinib; Drug: Sasanlimab Prefilled syringe; Drug: Encorafenib; Drug: Sasanlimab; Drug: SEA-TGT; Drug: Axitinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Percentage of participants with Dose-limiting toxicities (DLT)|Durable Objective Response Rate - Percentage of Participants With Objective Response|Objective Response Rate-Percentage of Participants with Objective Response</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Sub-Study A only Phase 2 only: Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) lasting for at lease 10 months according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1).; Phase 1 Primary Outcome: DLTs are a predefined set of observed adverse events that are at least possibly related to at least 1 of the investigational agents.; Sub-Study B only Phase 2 only: Percentage of participants with CR or PR according to RECIST v1.1.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>First dose (Cycle 1 Day 1) to end of first treatment cycle (about 21-28 days); First dose (Cycle 1 Day 1) to End of Treatment (up to about 24 months); each cycle is about 21 days; First dose (Cycle 1 Day 1) to End of Study Treatment (up to about 24 months); each cycle is about 28 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW IT ############ -->
<!-- ############################### -->
<!-- ############################### -->

<h3 id="new_it">NO NEW INTRATUMORAL TRIALS</h3><br>
<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING IT ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_it">Existing Trials - Intratumoral</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Changed status from recruiting to suspended</strong></td>
    <td>Non-Hodgkin lymphoma Hodgkin lymphoma or stage IV breast cancer</td>
    <td>Mayo Clinic</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_43">Study Arms</button></td>
    <td><p>Belinostat; Carfilzomib; Copanlisib Hydrochloride; Daratumumab; Fludeoxyglucose F-18; Gemcitabine Hydrochloride; Laboratory Biomarker Analysis; Nivolumab; Obinutuzumab; Pembrolizumab; Positron Emission Tomography; Rituximab; Romidepsin; Saline; Trastuzumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_521">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03432741" target="_blank">NCT03432741</a></td><td><select class="form-select" id="select_form_53" name="NCT03432741"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>High-grade glioma that has come back after a period of time during which the tumor could not be detected</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_44">Study Arms</button></td>
    <td><p>Laboratory Biomarker Analysis; Lapatinib; Lapatinib Ditosylate; Pharmacological Study; Therapeutic Conventional Surgery</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_521">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02101905" target="_blank">NCT02101905</a></td><td><select class="form-select" id="select_form_54" name="NCT02101905"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 210 days; Now recruiting</strong></td>
    <td>Histologically confirmed advanced and/or metastatic solid tumors that are refractory to standard therapy</td>
    <td>Guangzhou Sinogen Pharmaceutical Co. Ltd</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_45">Study Arms</button></td>
    <td>SGN1</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05103345" target="_blank">NCT05103345</a></td><td><select class="form-select" id="select_form_55" name="NCT05103345"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 391 days</strong></td>
    <td>MPP2+ glioblastoma that has come back (recurrent) or that is growing spreading or getting worse (progressive)</td>
    <td>City of Hope Medical Center</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_46">Study Arms</button></td>
    <td>Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery); Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04214392" target="_blank">NCT04214392</a></td><td><select class="form-select" id="select_form_56" name="NCT04214392"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 153 days; Primary Completion Date pushed later by 181 days</strong></td>
    <td>Head and neck or cervical cancer</td>
    <td>Hookipa Biotech GmbH</td>
<td><p>Early Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_47">Study Arms</button></td>
    <td>HB-201 IT; HB-201 IV; HB-201 IT</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04630353" target="_blank">NCT04630353</a></td><td><select class="form-select" id="select_form_57" name="NCT04630353"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo4" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="7">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_43" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients undergo FDG-PET and receive saline intralesionally on day 1. Patients also receive up to five additional injections of gemcitabine hydrochloride romidepsin belinostat carfilzomib copanlisib hydrochloride nivolumab trastuzumab daratumumab obinutuzumab pembrolizumab or rituximab intralesionally per investigator on day 1. Beginning 5 days later patients with nodal/extranodal mass undergo restaging FDG-PET and biopsy (if clinically feasible). Within 3-7 days patients with cutaneous disease undergo restaging photography and biopsy.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Copanlisib Hydrochloride; Procedure: Positron Emission Tomography; Drug: Belinostat; Biological: Rituximab; Biological: Trastuzumab; Biological: Daratumumab; Biological: Obinutuzumab; Drug: Romidepsin; Other: Saline; Biological: Nivolumab; Drug: Fludeoxyglucose F-18; Drug: Gemcitabine Hydrochloride; Other: Laboratory Biomarker Analysis; Biological: Pembrolizumab; Drug: Carfilzomib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of drug sensitivity as measured by injection site skin reaction</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Skin reactions will be assessed using the Cancer Therapy Evaluation Program (CTEP) active version of the Common Terminology Criteria for Adverse Events (CTCAE) and will consist of any grade 3 or higher treatment-related pain skin or subcutaneous tissue disorders. Incidence rates of skin reactions will be estimated by the number of patients with reactions divided by the total number of evaluable patients per disease type. Exact binomial 95% confidence intervals for the true incidence rate will be calculated.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 3 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_44" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive lapatinib ditosylate PO BID on days -2 to 0. Within 3-5 hours after last dose of lapatinib ditosylate patients undergo surgical resection of tumor on day 0. Within 30 days of surgical resection of tumor patients receive lapatinib ditosylate BID for 2 days every 7 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.|Patients undergo surgery on day 0. Within 30 days of surgical resection of tumor patients receive lapatinib ditosylate BID for 2 days every 7 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Procedure: Therapeutic Conventional Surgery; Drug: Lapatinib; Drug: Lapatinib Ditosylate; Other: Pharmacological Study; Other: Laboratory Biomarker Analysis</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>To Determine the Lapatinib Ditosylate Intratumoral Concentration (Pharmacokinetics)|To Determine the Ratio of Phosphorylated (p)EGFR/Total EGFR (PD) in Tumor Tissue</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>4 pk samples obtained: pretreatment pre-surgery post-surgery and interpolated pre-surgery each subject received 2500mg twice a day for two days.; A ratio of pEGFR/total EGFR at 80% reduction from a median value from the untreated reference group will be considered as the putative threshold to qualify a near complete inhibition of EGFR (at 80%).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline and day of surgery; Day of surgery</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_45" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Other</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>The standard 3+3 dose escalation algorithm will be applied to explore dose limiting toxicity (DLTs) in up to 5 sequential cohorts with 3- 6 patients and identify the maximally tolerated dose (MTD).||When the cohort is completed in Part 1 the Part 2 study could be started according to the SMC evaluation (If there is no DLT and there is the complete response [CR] or partial response [PR] observed at the cohort or at least all patients have stable disease [SD] result available for the tumor assessment).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: SGN1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of adverse events (AEs)|Incidence of SAEs|Objective response rate (ORR)|Disease control rate (DCR)|Progression Free Survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>"• The ORR is defined as the proportion of patients who achieve PR or better according to the RECIST v1.1. mRECIST is used to assess Hepatocellular carcinoma and LYRIC is used to assess Lymphoma as assessed by investigator; Signs symptoms or the clinical sequelae of a suspected interaction.; A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; • The DCR is defined as the proportion of patients who achieve SD or better according to the RECIST v1.1 mRECIST is used to assess Hepatocellular carcinoma and LYRIC is used to assess Lymphoma as assessed by investigator.; A congenital anomaly/birth defect; Important medical events that may not result in death be life-threatening or require hospitalization may be considered serious when based upon appropriate medical judgment they may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home blood dyscrasias or convulsions that do not result in inpatient hospitalization or the development of drug dependency or drug abuse.; Any abnormal laboratory test results (hematology serum chemistry or urinalysis) or other safety assessments (e.g. ECGs vital signs measurements) including those that worsen from baseline and was felt to be clinically significant in the medical and scientific judgment of the Investigator.; New conditions detected or diagnosed after study treatment administration even though it may have been present prior to the start of the study.; Events meeting the definition of an AE include:; An AE is any untoward medical occurrence in a patient or clinical investigation patient temporally associated with the use of a medicinal product whether or not considered related to the medicinal product.; Life-threatening; • PFS is defined as the time interval from date of first dose of SGN1 to the date of documented disease progression (iRECIST is used when the patient is suspected to be pseudo disease progression) or death due to any cause whichever occurs first.; In patient hospitalization or prolongation of existing hospitalization; An AE or suspected adverse reaction is considered ""serious"" if it results in any of the following outcomes:; Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or intensity of the condition.; Death; The efficacy endpoints include ORR DCR and PFS."</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From receiving study drug and throughout the study until 28 days after the last dosing; From signing the informed consent form until 28 days after the last dose.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_46" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Arm 1 participants will undergo resection/biopsy of their tumor and placement of a Rickham catheter at the site of the resection/biopsy. Patients receive chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes NCI SYs via single delivery starting on day 0 for 3 weekly cycles over 28 days. Each treatment cycle begins with one CAR T cell infusion delivered intracranial intratumoral or intracavitary [ICT] and lasts for 1 week. Beginning 1 week after cycle 3 patients may continue with CAR T cell treatment per principal investigator and patient discretion. Treatment continues in the absence of disease progression or unacceptable toxicity.|Arm 2 participants will undergo resection/biopsy of their tumor and placement of a Rickham catheter at the site of the resection/biopsy and the lateral ventricle. Patients receive chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes NCI SYs via dual delivery starting on day 0 for 3 weekly cycles over 28 days. Each treatment cycle begins with two CAR T cell infusions (intracranial intratumoral or intracavitary [ICT]) and also into the lateral ventricle (intracranial intraventricular [ICV]) and lasts for 1 week. Beginning 1 week after cycle 3 patients may continue with CAR T treatment per principal investigator and patient discretion. Treatment continues in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery); Biological: Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose limiting toxicity (DLT)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 5.0). Rate and associated 90% Clopper and Pearson binomial confidence limits (90% confidence interval) will be estimated for participants experiencing DLTs at the recommended phase 2 dose schedule. Tables will be created to summarize all toxicities and side effects by dose time post treatment organ severity and arm. 2. Cytokine Release Syndrome (CRS) 3. All other toxicities.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>28 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_47" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients with resectable stage I-III HPV 16+ genotype squamous cell cancer of the oropharynx.|Patients with resectable stage I-III HPV 16+ genotype squamous cell cancer of the oropharynx.|Patients with cervical cancer who have locally advanced squamous cell carcinoma with HPV 16+ genotype.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: HB-201 IV; Drug: HB-201 IT</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Immune response profiles in subjects with HPV 16+ Head and Neck and cervical cancer.|Immunologic response comparing IV and IT administration.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Measurement of antigen-specific CD8+ T cells in blood and tissue (E7E6 antigen specific assay).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Approximately 6-8 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW  CT ########### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="new_ct">New Trials - Cytotoxic</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Unresectable or metastatic melanoma</td>
    <td>BioNTech US Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_48">Study Arms</button></td>
    <td>NEO-PTC-01; IL-2; PD-1 therapy</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04625205" target="_blank">NCT04625205</a></td><td><select class="form-select" id="select_form_58" name="NCT04625205"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>HIV-1-infection</td>
    <td>Henry M. Jackson Foundation for the Advancement of Military Medicine</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_49">Study Arms</button></td>
    <td>VRC07-523LS; PGDM1400LS; N-803; Ad26.Mos4.HIV; MVA-BN-HIV; A244d11 gp120; ALFQ; Antiretroviral Therapy (ART)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05769569" target="_blank">NCT05769569</a></td><td><select class="form-select" id="select_form_59" name="NCT05769569"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Gastrointestinal Cancer; Chemotherapy-Induced Thrombocytopenia</td>
    <td>Hanny Al-Samkari MD</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_50">Study Arms</button></td>
    <td>Avatrombopag; Matching Placebo</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05772546" target="_blank">NCT05772546</a></td><td><select class="form-select" id="select_form_60" name="NCT05772546"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Epithelial Ovarian Cancer</td>
    <td>Radboud University Medical Center</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_51">Study Arms</button></td>
    <td>XP-DC vaccinations</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05773859" target="_blank">NCT05773859</a></td><td><select class="form-select" id="select_form_61" name="NCT05773859"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo5" class="accordion-toggle">  <td colspan="6">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_48" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Monotherapy - Dose 1|Monotherapy - Dose 2|NEO-PTC-01 in combination with a fixed dose of IL-2 (cohort will only be open in countries where IL-2 is approved)|The αPD-1 therapy will be introduced beginning 1 to 2 weeks post NEO-PTC-01 to patients who failed αPD-1/α programmed death ligand 1 (αPD-L1) therapy prior to enrollment in the NTC-001 study|Patients currently receiving PD-1/PD-L1 inhibitors (as single agent or in combination with cytotoxic T-lymphocyte-associated antigen-4 [CTLA4] inhibitors) as therapy for metastatic melanoma</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: IL-2; Drug: αPD-1 therapy; Biological: NEO-PTC-01</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Rate of adverse events (AEs) including serious adverse events (SAEs) and AEs leading to treatment discontinuation</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Rate of AEs including SAEs and AEs leading to treatment discontinuation and those AEs and SAEs detected during symptom-directed physical examinations (changes in safety laboratory evaluations physical examination findings and vital signs).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Day 1 to Week 52</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_49" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Active Group (ART with the addition of VRC07-523LS PGDM1400LS and N-803 in combination with Ad26.Mos4.HIV MVA-BN-HIV A244d11 gp120 and ALFQ vaccination)|Control Group (continue only with ART without further interventions)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: N-803; Biological: A244d11 gp120; Biological: Ad26.Mos4.HIV; Biological: VRC07-523LS; Biological: MVA-BN-HIV; Biological: PGDM1400LS; Combination Product: Antiretroviral Therapy (ART); Biological: ALFQ</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>To evaluate the safety of VRC07-523LS PGDM1400LS and N-803 in combination with Ad26.Mos4.HIV MVA-BN-HIV and A244d11 gp120/ALFQ vaccination in PLWH who initiated ART during AHI.|To evaluate the treatment combination on time to sustain viral rebound to ≥1000 copies/mL for 4 consecutive weeks AND has not declined by 0.2 log10</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>"Occurrence of ≥ grade 3 AE or SAE that are possibly probably or definitely related to the IPs during the study. Adverse events will be graded using ""DAIDS TABLE FOR GRADING THE SEVERITY OF ADULT AND PEDIATRIC ADVERSE EVENTS (DAIDS AE SEVERITY GRADING TABLE) V2.1 JULY 2017"" (https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf) where grade 1 is mild and grade 4 is potentially life threatening.; Time (days) from ATI to sustained viral rebound of ≥1000 copies/mL for 4 consecutive weeks AND has not declined by 0.2 log10 from the previous measurement."</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Through month 31</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_50" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>30 participants will be randomized into a 1:1 fashion and will be stratified based on the number of cytotoxic agents in the patient's chemotherapy regimen. Participants will complete study procedures as outlined:||Lead-In Period (Day 1 - 15)||Pre-determined dose of Avatrombopag 1x daily.|Participants failing to achieve a platelet count ≥100000/µL within 2 weeks will be considered a treatment failure (and will proceed to the end-of-study visit).||On-Cycle Period (Day 15 - up to Week 6)||• Pre-determined dose of Avatrombopag 1x daily.||Follow-up Period||End of Treatment on-site visit.|Follow-up visit 30-42 days after End of Treatment visit.|30 participants will be randomized into a 1:1 fashion and will be stratified based on the number of cytotoxic agents in the patient's chemotherapy regimen. Participants will complete study procedures as outlined:||Lead-In Period (Day 1 - 15)||Pre-determined dose of matching placebo 1x daily.|Participants failing to achieve a platelet count ≥100000/µL within 2 weeks will be considered a treatment failure (and will proceed to the end-of-study visit).||On-Cycle Period (Day 15 - up to Week 6)||• Pre-determined dose of matching placebo 1x daily.||Follow-up Period||End of Treatment on-site visit.|Follow-up visit 30-42 days after End of Treatment visit.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Avatrombopag; Drug: Matching Placebo</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Response Rate|Response Rate of CIT Treatment in Avatrombopag|Response Rate of CIT Treatment in Placebo Group</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The primary endpoint of this study is the comparison of the response rate between the avatrombopag arm and the placebo arm. A response is defined as achieving a platelet count ≥100000/µL within the 2 week lead-in period and then finishing at least 1 cycle of chemotherapy without CIT recurrence (no on-cycle dose-reduction or treatment delay due to thrombocytopenia and ability to receive another cycle of chemotherapy without dose-reduction or treatment delay defined as platelet count of ≥100000/µL at the start of the following cycle whether or not an additional cycle is planned).; Defined as the composite of successful initial platelet count recovery to ≥100000/µL within 15 days of initiation of study drug plus CIT prevention for one additional chemotherapy cycle (including at the completion of that cycle/start of the following cycle).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 6 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_51" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients in this arm will receive XP-DC vaccination in addition to standard-of-care treatment.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: XP-DC vaccinations</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of patients with an immunological response to XP-DC vaccination</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Immunologically responding patients are defined as:; Immunologically non-responding patients are defined as:; No T cells or T cells isolated from DTH biopsies that cannot be expanded or T cells that can be expanded but do not recognize tumor antigens or can recognize tumor antigens but do not display T effector functions i.e. lysis of tumor cell targets or release of IFN-α.; T cells isolated from vaccine challenged sites (DTH biopsies) that can be expanded and 1) express T cell receptors specific for the vaccine and 2) show effector functions measured by IFN-gamma secretion or cytolytic activity against tumor antigen expressing target cells.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>At DTH skin test after the second vaccination (approximately study week 10)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING CT ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_ct">Existing Trials - Cytotoxic</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Enrollment decreased by: 25; Trial completed</strong></td>
    <td>Cytomegalovirus Infections; Hematological Disease</td>
    <td>Shanghai General Hospital Shanghai Jiao Tong University School of Medicine</td>
<td><p>Phase 4</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_52">Study Arms</button></td>
    <td><p>donor derived cytomegalovirus specific T lymphocytes; Foscarnet; Ganciclovir</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_528">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03004261" target="_blank">NCT03004261</a></td><td><select class="form-select" id="select_form_62" name="NCT03004261"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 279 days; Enrollment decreased by: 15; Changed status from suspended to active</strong></td>
    <td>Early stage triple negative breast cancer</td>
    <td>Roswell Park Cancer Institute</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_53">Study Arms</button></td>
    <td><p>Celecoxib; Cyclophosphamide; Doxorubicin; Doxorubicin Hydrochloride; Paclitaxel; Recombinant Interferon Alfa-2b; Rintatolimod</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_528">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04081389" target="_blank">NCT04081389</a></td><td><select class="form-select" id="select_form_63" name="NCT04081389"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 198 days</strong></td>
    <td>Metastatic castration-resistant prostate cancer</td>
    <td>Aragon Pharmaceuticals Inc.</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_54">Study Arms</button></td>
    <td><p>Apalutamide; Abiraterone acetate; Prednisone; Placebo</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_528">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02257736" target="_blank">NCT02257736</a></td><td><select class="form-select" id="select_form_64" name="NCT02257736"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Start Date pushed later by 365 days</strong></td>
    <td>Colon Cancer Stage III</td>
    <td>Johannes Laengle MD PhD</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_55">Study Arms</button></td>
    <td><p>Capecitabine; Oxaliplatin; Fluorouracil; Leucovorin; Immunoscore assay; Physical exercise</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_528">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04488159" target="_blank">NCT04488159</a></td><td><select class="form-select" id="select_form_65" name="NCT04488159"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Primary Completion Date pushed later by 365 days</strong></td>
    <td>Invasive Carcinoma</td>
    <td>Melanoma Institute Australia</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_56">Study Arms</button></td>
    <td><p>Sonidegib; Imiquimod; Surgery; Best supportive care</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_528">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03534947" target="_blank">NCT03534947</a></td><td><select class="form-select" id="select_form_66" name="NCT03534947"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo6" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="7"><button type="button" class="btn btn-large btn-outline-primary">VIEW LARGE COMPANY TRIALS</button></td>
  </tr>
 <tr>  <td colspan="12" class="hiddenRow"> <div class="accordian-body collapse" id="demo6"><table class="table table-striped"><thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date pushed later by 211 days; Enrollment increased by: 36</strong></td>
    <td>HER2-positive advanced/metastatic gastric/gastroesophageal junction (GEJ) and esophageal adenocarcinoma</td>
    <td>AstraZeneca</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_57">Study Arms</button></td>
    <td><p>Fluorouracil (5-FU); Capecitabine; Durvalumab; Oxaliplatin; Trastuzumab; Trastuzumab deruxtecan; Cisplatin; Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_528">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04379596" target="_blank">NCT04379596</a></td><td><select class="form-select" id="select_form_67" name="NCT04379596"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
</div></td></tr>  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_52" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>The donor derived cytomegalovirus specific T lymphocytes (CMV-CTL) will be transfused to the patients. The patients will receive CMV-CTL cells when they are sero-positive for CMV-DNA 30 days after transplant. The CMV-DNA levels will be monitored weekly for at least 60 days after the transplant. If after the initial dose of CMV-CTL cells the patient develops a viral infection then they may be eligible to receive one additional injection of CMV-CTLs. If the CMV levels in the blood continue to rise after the dose of T cells then the patient will receive treatment with Ganciclovir or Foscarnet.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Foscarnet; Drug: Ganciclovir; Biological: donor derived cytomegalovirus specific T lymphocytes</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>30-day response rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The percentage of patient whose serum CMV-DNA becomes negative in 30 days.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>from the date of CMV-CTL infusion to 30 days after the infusion</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_53" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive celecoxib PO BID recombinant interferon alfa-2b IV over 20 minutes and rintatolimod IV on days 1-3 of weeks 1-3 as well as paclitaxel IV over 1 hour once weekly on day 1. Treatment continues for a total of 12 weeks in the absence of disease progression or unacceptable toxicity. 1-3 weeks after last dose of paclitaxel patients receive doxorubicin IV over 10 minutes and cyclophosphamide IV over 30 minutes. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Rintatolimod; Biological: Recombinant Interferon Alfa-2b; Drug: Paclitaxel; Drug: Cyclophosphamide; Drug: Celecoxib; Drug: Doxorubicin Hydrochloride; Drug: Doxorubicin</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Tumor-infiltrating CD8+ cytotoxic T lymphocyte (CTL)s|Tumor-infiltrating CD8+ cytotoxic T lymphocyte (CTL)s</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Will compare the tumor-infiltrating CD8+ CTLs in the pre-treatment and w week posttreatment biopsy samples of early stage triple negative breast cancer tissue following neo-adjuvant chemotherapy with paclitaxel with/without chemokine modulation (CKM): rintatolimod (a selective toll-like receptor-3 agonist) celecoxib + interferon (IFN)-alpha.; Will compare the tumor-infiltrating CD8+ CTLs in the pre-treatment and 4 week posttreatment biopsy samples of early stage triple negative breast cancer tissue following neo-adjuvant chemotherapy with paclitaxel with/without chemokine modulation (CKM): rintatolimod (a selective toll-like receptor-3 agonist) celecoxib + interferon (IFN)-alpha.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>4 week post-treatment; Baseline (Pre-treatment)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_54" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Placebo Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive apalutamide 240 milligram (mg) (4*60 mg tablets) and abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily on an empty stomach and 5 mg prednisone (P) AAP twice daily until disease progression unacceptable toxicity or end of treatment whichever occurs first. After unblinding participants will be offered further treatment as defined in the Open-Label Extension (OLE) or Long-Term Extension (LTE) phase (AAP + open label apalutamide or AAP alone).|Participants will receive matching Placebo of apalutamide and abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily on an empty stomach and 5 mg prednisone (P) AAP twice daily until disease progression unacceptable toxicity or end of treatment whichever occurs first. After unblinding participants will be offered further treatment as defined in the OLE or LTE phase (AAP + open label apalutamide or AAP alone).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Apalutamide; Drug: Placebo; Drug: Abiraterone acetate; Drug: Prednisone</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Radiographic Progression-free Survival (rPFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (=) 2 new lesions compared to baseline was observed in less than () 12 weeks from randomization and was confirmed by a second bone scan taken =6 weeks later showing =2 additional new lesions (a total of =4 new lesions compared to baseline) b) the first bone scan with =2 new lesions compared to baseline was observed in =12 weeks from randomization and the new lesions were verified on the next bone scan =6 weeks later (a total of =2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 3 years and 4 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_55" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Immunoscore low (I-Low; I0-1): 3 months CAPOX (oxaliplatin 130 mg/m2 IV over 2 h and capecitabine 1000 mg/m2 PO twice daily (days 1-14). 21-day treatment cycle.). Concomitantly standardised physical excise (stair walking excise twice a week for 12 weeks) which will be monitored by an electronic sports device.|Immunoscore intermediate-high (I-IntHi; I2-3): 6 months FOLFOX (oxaliplatin 85 mg/m2 IV (on day 1) and folinic acid 200 mg/m2 IV over 2 h followed by a bolus of fluorouracil 400 mg/m2 IV over 2-4 min followed by fluorouracil 600 mg/m2 IV over 22 h (for 2 consecutive days). 14-day treatment cycle.)|Immunoscore high (I high; I4): no adjuvant treatment.|TNM-based low-risk (pT1 pT2 or pT3 and pN1): 3 months CAPOX (oxaliplatin 130 mg/m2 IV over 2 h and capecitabine 1000 mg/m2 PO twice daily (days 1-14). 21-day treatment cycle.)|TNM-based high-risk (pT4 and/or pN2): 6 months FOLFOX (oxaliplatin 85 mg/m2 IV (on day 1) and folinic acid 200 mg/m2 IV over 2 h followed by a bolus of fluorouracil 400 mg/m2 IV over 2-4 min followed by fluorouracil 600 mg/m2 IV over 22 h (for 2 consecutive days). 14-day treatment cycle.)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Capecitabine; Other: Physical exercise; Drug: Fluorouracil; Device: Immunoscore® assay; Drug: Leucovorin; Drug: Oxaliplatin</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Disease-free survival (DFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Impact of Immunoscore stratification on DFS at 3 years (time from surgery to first observation of disease recurrence or death due to any cause)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_56" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Other</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Sonidegib 200mg taken orally once a day for 12 weeks. COMPLETE OR PARTIAL RESPONSE WITH SUPERFICAL REMNANT LESION For patients with a complete response or a partial response resulting in a superficial lesion treatment with topical imiquimod for 5 days a week for 6 weeks will be prescribed.|Sonidegib 200mg taken orally once a day for 12 weeks. PARTIAL RESPONSE WITH REMNANT INVASIVE LESION For patients with a no change on BCC size / depth or patients with a partial response but a remaining invasive lesion will have surgical excscion of the remaining lesion.|Sonidegib 200mg taken orally once a day for 12 weeks. PROGRESSIVE DISEASE Patients with lesions that have progressed in size and/or depth will receive the best supportive care deemed appropriate by the treating clinician. This may be surgery imiquimod a clinical trial treatment radiotherapy or any combination of these interventions.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Other: Best supportive care; Drug: Sonidegib; Drug: Imiquimod; Procedure: Surgery</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Neoadjuvant treatment response determined by optical coherence tomography</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The size and spread of abnormal skin structures associated with basal cell carcinoma detected by optical coherence tomography.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>12 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_57" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>T-DXd and 5-fluorouracil (5-FU)|T-DXd and capecitabine|T-DXd and durvalumab|T-DXd 5-FU and oxaliplatin|T-DXd capecitabine and oxaliplatin|T-DXd 5-FU and durvalumab|T-DXd capecitabine and durvalumab|Trastuzumab 5-FU or capecitabine and cisplatin or oxaliplatin|T-DXd monotherapy|T-DXd 5-FU or capecitabine and oxaliplatin|T-DXd 5-FU or capecitabine and pembrolizumab|T-DXd and pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Capecitabine; Drug: Trastuzumab deruxtecan; Biological: Trastuzumab; Biological: Durvalumab; Drug: Cisplatin; Drug: Fluorouracil (5-FU); Biological: Pembrolizumab; Drug: Oxaliplatin</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Part 1: Occurrence of adverse events (AEs) and serious adverse events (SAEs)|Part 2: Objective Response Rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Confirmed ORR per RECIST 1.1 is the percentage of patients with Complete Response or Partial Response that is subsequently confirmed.; Occurrence of AEs and SAEs graded according to NCI CTCAE v5.0</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>An average of approximately 12 months.; Safety will be assessed for approximately 24 months from informed consent.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW IA ############ -->
<!-- ############################### -->
<!-- ############################### -->

<h3 id="new_ia">NO NEW IMMUNE ACTIVATION TRIALS</h3><br>
<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING IA ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_ia">Existing Trials - Immune Activation</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 301 days; Trial completed</strong></td>
    <td>Hematological Malignancies</td>
    <td>Stefanie Sarantopoulos MD PhD.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_58">Study Arms</button></td>
    <td>fostamatinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02611063" target="_blank">NCT02611063</a></td><td><select class="form-select" id="select_form_68" name="NCT02611063"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>Autoimmune Hemolytic Anemia</td>
    <td>Institute of Hematology & Blood Diseases Hospital</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_59">Study Arms</button></td>
    <td>Linperlisib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05676697" target="_blank">NCT05676697</a></td><td><select class="form-select" id="select_form_69" name="NCT05676697"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 731 days; Now recruiting</strong></td>
    <td>Sepsis; Gram-Negative Bacterial Infections</td>
    <td>The Third Xiangya Hospital of Central South University</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_60">Study Arms</button></td>
    <td>Unfractionated Heparin</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04861922" target="_blank">NCT04861922</a></td><td><select class="form-select" id="select_form_70" name="NCT04861922"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 427 days; Trial completed</strong></td>
    <td>HIV Infection</td>
    <td>McGill University Health Centre/Research Institute of the McGill University Health Centre</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_61">Study Arms</button></td>
    <td>Metformin</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02659306" target="_blank">NCT02659306</a></td><td><select class="form-select" id="select_form_71" name="NCT02659306"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 334 days</strong></td>
    <td>HIV Infection</td>
    <td>Massachusetts General Hospital</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_62">Study Arms</button></td>
    <td>Panobinostat; Pegylated Interferon-alpha2a</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02471430" target="_blank">NCT02471430</a></td><td><select class="form-select" id="select_form_72" name="NCT02471430"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Start Date pushed later by 182 days</strong></td>
    <td>HRD/FAD solid tumours</td>
    <td>Maastricht University</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_63">Study Arms</button></td>
    <td><p>CP-506; Carboplatin; Immune checkpoint inhibitor</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_533">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04954599" target="_blank">NCT04954599</a></td><td><select class="form-select" id="select_form_73" name="NCT04954599"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Start Date pushed later by 212 days</strong></td>
    <td>Mucosal Melanoma</td>
    <td>Melanoma Institute Australia</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_64">Study Arms</button></td>
    <td><p>Pembrolizumab; Lenvatinib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_533">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05545969" target="_blank">NCT05545969</a></td><td><select class="form-select" id="select_form_74" name="NCT05545969"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo7" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="7">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_58" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Subjects will receive fostamatinib 100 mg qd 150 mg qd or 100 mg bid with dosage determined by the modified continual reassessment method. The treatment period begins at baseline 90 days after transplant and continues for up to 1 year after transplant. In patients with steroid-refractory cGVHD who are also included on this study these subjects also receive fostamatinib 100mg qd 150mg qd or 100mg bid dosage determined by the modified continual reassessment method.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: fostamatinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Evaluate maximum tolerated dose of fostamatinib delivered following allogenic transplantation</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Grade  or = II aGVHD of the gut or liver or Grade III aGVHD of the skin lasting  7 days and related to the agent; ANC0.5 x 10e9/L for 5 days and attributable to the agent; Grade 3 toxicity from the agent in the cardiac dermatologic gastrointestinal hepatic pulmonary renal/genitourinary or neurologic categories that lasts  5 days; absolute neutrophil count (ANC) of Grade 3 or 4 plus fever attributable to the agent; fostamatinib related mortality (TRM); three dose levels are considered: 100 mg qd 150 mg qd 100 mg bid dose limiting toxicity is any of the following; platelet  25 x 10e 9/L and attributable to the agent</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>day 60 after fostamatinib initiation</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_59" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Linperlisib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall response rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Percentage of patients with hematological response. Hematological response is evaluated by hemoglobin and other hemolysis-related laboratory indicators.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>6-12 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_60" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Placebo Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>A bottle solution of Heparin Sodium (2ml:12500IU) is added to 48 ml saline and administered intravenously continuously for 24 hours (10 unit/kgBW/hour) which last 5 days or until the death or discharge.|The same amount of 0.9% saline as the heparin group (50ml) will be administered in the placebo group.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Unfractionated Heparin</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>All-Cause Mortality</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Death from all causes at 28-days</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>28 Days after randomization</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_61" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Assessment will be done at the baseline during and after 12 week of metformin use.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Metformin</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Decrease in the size of the HIV reservoir</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>12 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_62" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants in Arm A will receive panobinostat as an oral tablet on days 0 2 and 4 of the treatment week. The dose of panobinostat will be a 15 mg tablet.|Participants in Arm B will receive one subcutaneous injection of pegylated interferon-alpha2a on day 0. The dose of pegylated IFN-alpha2a will be 180 mcg. Simultaneously with interferon-alpha2a a 15 mg tablet of panobinostat will be administered on day 0. Participants will also receive panobinostat as an oral tablet on days 2 and 4 of the treatment week.|Participants in Arm C will receive one subcutaneous injection of pegylated interferon-alpha2a on day 0.The dose of pegylated IFN-alpha2a will be 180 mcg.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Pegylated Interferon-alpha2a; Drug: Panobinostat</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Occurrence of Grade ≥ 1 Adverse Events (AEs)|Change in CD4 T Cell-Associated Proviral HIV-1 DNA from Baseline</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Cumulative frequency and severity of Grade ≥ 1 adverse events Grade ≥ 1 lab abnormalities or serious adverse events; Operational measurement of HIV-1 reservoir</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Measured through 1 week after administration of panobinostat and/or interferon-alpha2a; Measured through 1 month after administration of panobinostat and/or interferon-alpha2a</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_63" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Multiple ascending dose cohorts dosing CP-506 monotherapy in all patients up to a maximally tolerated or maximally feasible dose Intervention: Drug: CP-506|Expansion cohort dosing CP-506 monotherapy in patients at recommended phase 2 dose (RP2D) Intervention: Drug: CP-506|Multiple ascending dose cohorts dosing CP-506 in combination with carboplatin in all patients up to a maximally tolerated or maximally feasible dose Intervention: Drug: CP-506|Expansion cohort dosing CP-506 in combination with carboplatin in patients at recommended phase 2 dose (RP2D) Intervention: Drug: CP-506|Multiple ascending dose cohorts dosing CP-506 in combination with Immune Checkpoint Inhibitor in all patients up to a maximally tolerated or maximally feasible dose Intervention: Drug: CP-506|Expansion cohort dosing CP-506 in combination with Immune Checkpoint Inhibitor in patients at recommended phase 2 dose (RP2D) Intervention: Drug: CP-506</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Carboplatin; Drug: Immune checkpoint inhibitor; Drug: CP-506</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of treatment-emergent adverse events including dose-limiting toxicities|Incidence of clinically significant abnormal measurements in physical examination vital signs electrocardiogram (ECG) lab tests and ECOG performance status</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The proportion of patients with treatment-emergent (serious) adverse events including dose-limiting toxicity (DLT); Physical examination; vital signs; electrocardiogram (ECG); haematology; clinical chemistry; urinalysis; plasma/renal makers; tumour markers; ECOG performance status</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline until 60 days after last administration of CP-506</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_64" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Neoadjuvant pembrolizumab & lenvatinib for 6 weeks followed by definitive surgery then adjuvant pembrolizumab alone for 46 weeks</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Lenvatinib; Drug: Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Change in immune cell expression of HIF1 and immune cell densities|Pathological response rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Tumour and immune cell expression of HIF1a and immune cell densities will be compared between baseline and day 8 melanoma tissue biopsies.; Proportion of patients with complete absence of residual melanoma cells in the the planned resected tumour site(s) at week 6 surgery</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>6 weeks; Baseline week 1 week 6</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######## FDA APPROVALS ######## -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="approvals">Drug Approvals/Applications</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0" class="fda">
  <thead>
    <tr>
      <th><h3>Company</h3></th>
      <th><h3>Update</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Glenmark</td>
    <td>Glenmark receives acceptance from U.S. FDA on its IND application for GRC 54276 to proceed with a Phase 1/2 first-in-human clinical study of the molecule for the treatment of patients with advanced solid tumors and lymphomas</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/" target="_blank"></a></td><td><select class="form-select" id="select_form_75" name=""><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo8" class="accordion-toggle" style = "background-color: #E1EBEE;">    <td>FORE Biotherapeutics</td>
    <td>FORE Biotherapeutics Receives FDA Orphan Drug Designation for FORE8394 for the Treatment of Primary Brain and CNS Malignancies</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05503797" target="_blank">NCT05503797</a></td><td><select class="form-select" id="select_form_76" name="NCT05503797"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_501" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '150MG/VIAL' '50MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['150MG/15ML (10MG/ML)' '450MG/45ML (10MG/ML)' '50MG/5ML (10MG/ML)' '600MG/60ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>CISPLATIN</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Nov 8 1988</td>
          <td>INJECTABLE;INJECTION</td>
          <td>1MG/ML</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['10MG/VIAL' '50MG/VIAL']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL-AQ</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Jul 18 1984</td>
          <td>INJECTABLE;INJECTION</td>
          <td>0.5MG/ML</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['500MG/20ML (25MG/ML)' '1GM/40ML (25MG/ML)' '100MG/4ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_502" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>VEMURAFENIB</td>
          <td>ZELBORAF</td>
          <td>HOFFMANN LA ROCHE</td>
          <td>Aug 17 2011</td>
          <td>TABLET;ORAL</td>
          <td>240MG</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_504" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>tocilizumab</td>
          <td>Actemra</td>
          <td>Genentech Inc.</td>
          <td>['11/19/2018' '10/21/2013' '1/8/2010']</td>
          <td>['Subcutaneous' 'Intravenous']</td>
          <td>['162MG/0.9ML' '80MG/4ML (20MG/ML)' '200MG/10ML (20MG/ML)' '400MG/20ML (20MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_507" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '150MG/VIAL' '50MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['150MG/15ML (10MG/ML)' '450MG/45ML (10MG/ML)' '50MG/5ML (10MG/ML)' '600MG/60ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_508" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>durvalumab</td>
          <td>Imfinzi</td>
          <td>AstraZeneca UK Ltd</td>
          <td>5/1/2017</td>
          <td>Intravenous</td>
          <td>['120MG/2.4ML (50MG/ML)' '500MG/10ML (50MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_509" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>brentuximab vedotin</td>
          <td>Adcetris</td>
          <td>Seagen Inc.</td>
          <td>8/19/2011</td>
          <td>Intravenous</td>
          <td>50MG</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_513" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '150MG/VIAL' '50MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['150MG/15ML (10MG/ML)' '450MG/45ML (10MG/ML)' '50MG/5ML (10MG/ML)' '600MG/60ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['500MG/20ML (25MG/ML)' '1GM/40ML (25MG/ML)' '100MG/4ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_514" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>durvalumab</td>
          <td>Imfinzi</td>
          <td>AstraZeneca UK Ltd</td>
          <td>5/1/2017</td>
          <td>Intravenous</td>
          <td>['120MG/2.4ML (50MG/ML)' '500MG/10ML (50MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_516" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>AVAPRITINIB</td>
          <td>AYVAKIT</td>
          <td>BLUEPRINT MEDICINES</td>
          <td>['Jan 9 2020' 'Jun 16 2021']</td>
          <td>TABLET;ORAL</td>
          <td>['25MG' '50MG' '200MG' '100MG' '300MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_517" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '150MG/VIAL' '50MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['150MG/15ML (10MG/ML)' '450MG/45ML (10MG/ML)' '50MG/5ML (10MG/ML)' '600MG/60ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_518" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CISPLATIN</td>
          <td>CISPLATIN</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Nov 8 1988</td>
          <td>INJECTABLE;INJECTION</td>
          <td>1MG/ML</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['10MG/VIAL' '50MG/VIAL']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL-AQ</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Jul 18 1984</td>
          <td>INJECTABLE;INJECTION</td>
          <td>0.5MG/ML</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCEFREZ</td>
          <td>SUN PHARM</td>
          <td>May 3 2011</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/VIAL' '20MG/VIAL']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>ACCORD HLTHCARE</td>
          <td>['Jun 8 2011' 'Apr 20 2012']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['20MG/ML (20MG/ML)' '20MG/0.5ML (40MG/ML)' '160MG/8ML (20MG/ML)' '80MG/2ML (40MG/ML)' '80MG/4ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>ACTAVIS LLC</td>
          <td>['Apr 12 2013' 'Sep 21 2015']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['20MG/ML (20MG/ML)' '80MG/4ML (20MG/ML)' '160MG/8ML (20MG/ML)' '140MG/7ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>APOTEX INC</td>
          <td>Jan 11 2012</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['20MG/0.5ML (40MG/ML)' '80MG/2ML (40MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>HOSPIRA INC</td>
          <td>['Jan 24 2017' 'Mar 8 2011' 'Jun 23 2016']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['20MG/ML (20MG/ML)' '160MG/16ML (10MG/ML)' '120MG/6ML (20MG/ML)' '20MG/2ML (10MG/ML)' '160MG/8ML (20MG/ML)' '80MG/8ML (10MG/ML)' '80MG/4ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>PFIZER LABS</td>
          <td>Mar 13 2014</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['130MG/13ML (10MG/ML)' '80MG/8ML (10MG/ML)' '200MG/20ML (10MG/ML)' '20MG/2ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SANDOZ</td>
          <td>Jun 29 2011</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/16ML (10MG/ML)' '80MG/8ML (10MG/ML)' '20MG/2ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SHILPA</td>
          <td>Dec 22 2015</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['20MG/ML (20MG/ML)' '80MG/4ML (20MG/ML)' '160MG/8ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SUN PHARM</td>
          <td>Jan 8 2019</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['20MG/ML (20MG/ML)' '80MG/4ML (20MG/ML)' '160MG/8ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>TAXOTERE</td>
          <td>SANOFI AVENTIS US</td>
          <td>['Aug 2 2010' 'Aug 3 2010' 'Apr 13 2012' 'May 14 1996']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['20MG/ML (20MG/ML)' '40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**' '80MG/4ML (20MG/ML)' '160MG/8ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['500MG/20ML (25MG/ML)' '1GM/40ML (25MG/ML)' '100MG/4ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
            <tr>
          <td>atezolizumab</td>
          <td>Tecentriq</td>
          <td>Genentech Inc.</td>
          <td>['3/8/2019' '5/18/2016']</td>
          <td>Intravenous</td>
          <td>['1200MG/20ML (60MG/ML)' '840MG/14ML (60MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_519" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['9/4/2014' '1/15/2015']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_520" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '150MG/VIAL' '50MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['150MG/15ML (10MG/ML)' '450MG/45ML (10MG/ML)' '50MG/5ML (10MG/ML)' '600MG/60ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>CISPLATIN</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Nov 8 1988</td>
          <td>INJECTABLE;INJECTION</td>
          <td>1MG/ML</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['10MG/VIAL' '50MG/VIAL']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL-AQ</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Jul 18 1984</td>
          <td>INJECTABLE;INJECTION</td>
          <td>0.5MG/ML</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['500MG/20ML (25MG/ML)' '1GM/40ML (25MG/ML)' '100MG/4ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
            <tr>
          <td>ipilimumab</td>
          <td>Yervoy</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>3/25/2011</td>
          <td>Intravenous</td>
          <td>['50MG/10ML (5MG/ML)' '200MG/40ML (5MG/ML)']</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['8/27/2021' '10/4/2017' '12/22/2014']</td>
          <td>Intravenous</td>
          <td>['100MG/10ML' '40MG/4ML' '240MG/24ML' '120MG/12ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_521" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>LAPATINIB DITOSYLATE</td>
          <td>TYKERB</td>
          <td>NOVARTIS</td>
          <td>Mar 13 2007</td>
          <td>TABLET;ORAL</td>
          <td>EQ 250MG BASE</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_528" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CAPECITABINE</td>
          <td>XELODA</td>
          <td>HOFFMANN LA ROCHE</td>
          <td>Apr 30 1998</td>
          <td>TABLET;ORAL</td>
          <td>['500MG' '150MG']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>CISPLATIN</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Nov 8 1988</td>
          <td>INJECTABLE;INJECTION</td>
          <td>1MG/ML</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['10MG/VIAL' '50MG/VIAL']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL-AQ</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Jul 18 1984</td>
          <td>INJECTABLE;INJECTION</td>
          <td>0.5MG/ML</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>ADRUCIL</td>
          <td>PHARMACIA AND UPJOHN</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>50MG/ML</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>CARAC</td>
          <td>VALEANT PHARMS NORTH</td>
          <td>Oct 27 2000</td>
          <td>CREAM;TOPICAL</td>
          <td>0.5%</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>EFUDEX</td>
          <td>BAUSCH</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>['SOLUTION;TOPICAL' 'CREAM;TOPICAL']</td>
          <td>['2%' '5%']</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>FLUOROPLEX</td>
          <td>ALMIRALL</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>CREAM;TOPICAL</td>
          <td>1%</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>FLUOROPLEX</td>
          <td>ELORAC</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>SOLUTION;TOPICAL</td>
          <td>1%</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>FLUOROURACIL</td>
          <td>SPECTRUM PHARMS</td>
          <td>['Approved Prior to Jan 1 1982' 'Jul 29 2016']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['2.5GM/50ML (50MG/ML)' '500MG/10ML (50MG/ML)']</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>TOLAK</td>
          <td>HILL DERMACEUTICALS</td>
          <td>Sep 18 2015</td>
          <td>CREAM;TOPICAL</td>
          <td>4%</td>
            </tr>
            <tr>
          <td>OXALIPLATIN</td>
          <td>ELOXATIN</td>
          <td>SANOFI AVENTIS US</td>
          <td>['Aug 9 2002' 'Jan 31 2005' 'Nov 17 2006']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['200MG/40ML (5MG/ML)' '50MG/10ML (5MG/ML)' '100MG/20ML (5MG/ML)' '100MG/VIAL' '50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**']</td>
            </tr>
            <tr>
          <td>OXALIPLATIN</td>
          <td>OXALIPLATIN</td>
          <td>TEVA PHARMS</td>
          <td>Aug 7 2009</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['50MG/10ML (5MG/ML)' '100MG/20ML (5MG/ML)']</td>
            </tr>
            <tr>
          <td>durvalumab</td>
          <td>Imfinzi</td>
          <td>AstraZeneca UK Ltd</td>
          <td>5/1/2017</td>
          <td>Intravenous</td>
          <td>['120MG/2.4ML (50MG/ML)' '500MG/10ML (50MG/ML)']</td>
            </tr>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['9/4/2014' '1/15/2015']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>trastuzumab</td>
          <td>Herceptin</td>
          <td>Genentech Inc.</td>
          <td>['2/10/2017' '9/25/1998']</td>
          <td>Intravenous</td>
          <td>['150MG' '420MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_533" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['9/4/2014' '1/15/2015']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<center><button type="submit" value="submit">Submit</button></center></div></form><br><p><strong> <em>Disclaimer: This weekly digest is a product created exclusively by Lexidyne LLC, in collaboration with Janssen. The intended purpose is to identify clinical phase assets with new data related to lung cancer, priority mechanisms of action, local/intratumoral delivery, and/or increased potency for acquisition & business development consideration. </em> </strong></p><p><em>Sources used include but are not limited to: PubMed, ClinicalTrials.gov, ASCO, AACR, NIH, EU Clinical Trials Register, European Pharmaceutical Review, FDA.gov, PRNewsWire, FiercePharma, and BioSpace. </em> </p><center><div class="subscription"><a href="https://docs.google.com/forms/d/e/1FAIpQLSffyxD4xZGkc99oZTy9lF0xPdIaqUMfCVpI2lWJzBkH3uDEag/viewform" target="_blank">Subscribe</a></div><div class="subscription"><p>|</p></div><div class="subscription"><a href="https://docs.google.com/forms/d/e/1FAIpQLSdaRqTScaPylLdbIIgAaWs3eYn3wMcF_qF408_-D9caWHAgLw/viewform" target="_blank">Unsubscribe</a></div><div class="subscription"><p>|</p></div><div class="subscription"><a href="https://docs.google.com/forms/d/e/1FAIpQLSdSCfl2l2sV2jo-vFfym-VPpzyEs5M0cRRPY5TmBIZ-nR6gSQ/viewform" target="_blank">Feedback</a></div></center>
